

CURRICULUM VITAE

Dr. Anthony Bernard Miller

Business address

Dalla Lana School of Public Health
University of Toronto
Health Sciences Building
155 College Street, Toronto, Ontario, M5T 3M7
e-mail: ab.miller@utoronto.ca

Home address

136 Charles Street, Port Hope, Ontario, L1A 1T3, Canada
Tel + 1 905 885 0253
e-mail: ab.miller@sympatico.ca

Education

Cranbrook College, Ilford	1936-1939
Friend's School, Saffron Walden	1939-1949
Selwyn College, Cambridge	1949-1952
St. Bartholomew's Hospital Medical School	1952-1955

Qualifications

B.A. (Cantab) (Pathology) 1952; M.B. (Cantab) 1956; B.Chir. (Cantab) 1955;
M.R.C.P. (London) (Internal Medicine) 1964; M.F.C.M. (U.K.) (Community Medicine)
1972; F.R.C.P.(C) (Medical Science) 1972; M.A. (Cantab), 2002; M.D. (Cantab), 2006.

Honours

Prize in Natural Sciences, Selwyn College Cambridge, 1951
Fellow, Faculty of Community Medicine (later Public Health), UK, 1977
Fellow, American College of Epidemiology, 1985
Fellow, Royal College of Physicians of London, England, 1987
National Health Scientist, Health and Welfare Canada, 1988-93
First O Harold Warwick Prize (Eli Lilly-National Cancer Institute of Canada) for Leadership
in Cancer Control, 1993.
Distinguished Achievement Award, American Society for Preventive Oncology, 1994.
Anthony B Miller Award for Excellence in Research Established, Graduate Department of
Community Health, University of Toronto, 1997
Lilienfeld Award, American College of Epidemiology, Epidemiology Section American
Public Health Association, Canadian Society of Epidemiology and Biostatistics,
2001.
Medal of Honour, International Agency for Research on Cancer, Lyon, 2003.

First Geoffrey R. Howe Distinguished Contributions Award, Canadian Society of Epidemiology and Biostatistics, 2009
26th International Papillomavirus Conference Honour Award, 2010.
Member, Order of Canada, 2019.

Professional Appointments

House Officer, Oldchurch Hospital, Romford, August 1955 - February 1957
Medical Officer, Royal Air Force Netheravon (National Service), April 1957 - March 1959
Senior House Officer in Medicine, Luton and Dunstable Hospital, April 1959 – February 1960
Medical Registrar, Luton and Dunstable Hospital. March 1960 - September 1962
Honorary Clinical Assistant, Brompton Hospital, London, November 1960 - April 1966
Member of Scientific Staff, Medical Research Council, Tuberculosis and Chest Diseases Unit, Brompton Hospital, London, October 1962 - April 1971.
Honorary Senior Lecturer, Institute of Diseases of the Chest, Brompton Hospital, London, January 1970 - April 1971
Assistant Executive Director (Epidemiology), National Cancer Institute of Canada, April 1971-76
Director, National Cancer Institute of Canada Clinical Trials Group, Toronto, April 1971 – March 1980
Director, Epidemiology Unit, National Cancer Institute of Canada, Toronto, April 1971 – June 1986
Associate Clinical Professor, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, April 1972 - June 1976
Associate Professor, Department of Preventive Medicine and Biostatistics, University of Toronto, June 1972 - June 1977
Professor, Department of Preventive Medicine and Biostatistics, University of Toronto, July 1977 - June 1997
Honorary Associate Staff Member, Department of Surgery, Mount Sinai Hospital, Toronto January 1980 - June, 1992
Director, Canadian National Breast Screening Study, January 1980 -
Director, M.Sc./Ph.D. Programme in Epidemiology, Graduate Dept. of Community Health, University of Toronto, July 1986 - June 1991
Director, WHO Collaborating Centre for Evaluation of Screening for Cancer, University of Toronto, 1991 - 2000
Visiting Scientist, Cancer and Palliative Care Unit, World Health Organization, Geneva, Switzerland, January - June, 1991.
Chairman, Department of Preventive Medicine and Biostatistics, University of Toronto, July 1992 - June 1996
Special Expert, Early Detection Branch, Division of Cancer Prevention and Control, National Cancer Institute, Bethesda MD, November 1996-May 1997.
Professor Emeritus, Department of Public Health Sciences, University of Toronto, July

1997-August 2008

Senior Epidemiologist, International Agency for Research on Cancer, January 1998-August 1999.

Acting Chief, Unit of Chemoprevention, International Agency for Research on Cancer, Lyon, September 1998-August 1999.

Supervisor, Division of Epidemiology, Deutsches Krebsforschungszentrum Heidelberg, February 1999-August 1999.

Head, Division of Clinical Epidemiology, Deutsches Krebsforschungszentrum Heidelberg, September 1999-April 2003

Professor Emeritus, Dalla Lana School of Public Health, University of Toronto, August 2008-

Associate Director, Research, Dalla Lana School of Public Health, University of Toronto, January 2009-December, 2010

Visiting Senior Scientist, International Agency for Research on Cancer, Lyon, France, September 2011-January 2012.

Professional Organizations

Founder member, International Association for the Study of Lung Cancer, 1970-92; Director 1976-1978.

Founder member, Canadian Oncology Society, 1976-, Secretary treasurer, 1976 -1979, President 1980 - 1981, Honorary editor, 1982 - 1992.

Founder member, American Society of Preventive Oncology, Director 1977-1981, President Elect 1981-1982, President, 1983-1985.

Advisory Committees and Expert Groups

Member, Ad Hoc Committee on Mammography, Canadian Association of Radiologists, 1972 - 1973

Member Working Cadre, National Bladder Cancer Project, U.S.A., 1973 - 1975

Member of Federal Task Force on Screening for Carcinoma of the Cervix, Canada, 1974 - 1976

Rapporteur, Second World Health Organization (WHO) Consultation on Standardization of Hospital Based Cancer Registries, 1974

Member of the Epidemiology Committee, Breast Cancer Task Force, 1973 - 1975; Chairman, 1975 - 1977

Member, Ontario Medical Association Section of Radiology, Sub-Committee on Breast Cancer Screening, 1976 - 1977

Member, Working Group for the Review of the U.S. Breast Cancer Detection Demonstration Projects, 1976 - 1978

Rapporteur, WHO Consultation on Standardization of Reporting of Results of Cancer Treatment, 1977

Chairman, International Union against Cancer (UICC) Workshop on Screening for Cancer, Toronto, 1978

Member, UICC Committee on Controlled Therapeutic Trials, 1978 - 1982

Member, UICC Multidisciplinary Project on Breast Cancer, 1978 - 1986
Chairman, WHO Meeting on Standardization of Reporting Results of Cancer Treatment, 1979
Member, Advisory Committee on Records and Registries, National Cancer Institute of Canada (NCIC), 1979 - 1987
Member, Subcommittee on Screening and Prevention, NCIC, 1979 - 1988
Member, Cancer Control Advisory Committee, U.S. National Cancer Institute, 1980
Member, Board of Scientific Counsellors, Division of Resources, Centers and Community Activities, U.S. National Cancer Institute, 1980 - 1982
Member, Reconvened Federal Task Force on Screening for Carcinoma of the Cervix, 1980 - 1982
Member, US National Academy of Sciences Committee on Diet, Nutrition and Cancer, 1980-1983
Member, Special Advisory Committee on Carcinogens of the Advisory Council on Occupational Health and Occupational Safety, Government of Ontario, 1980 - 1984
Member, Research Advisory Panel for the Royal Commission on Matters of Health and Safety Arising from the Use of Asbestos in Ontario, 1981 - 1984
Member, Grants Panel E, NCIC, 1981 - 1985
Member, Scientific Council, International Agency for Research on Cancer (IARC), Lyon, 1982 - 1984; Chairman 1984 - 1985.
Chairman, UICC Project on Screening, 1982-93, member 1993-94.
Chairman, WHO Consultation on Breast Self-Examination, Geneva, 1983
Member, Oversight Committee for the Radio Epidemiologic Tables, U.S. National Academy of Sciences, 1983 - 1984
Member, American Cancer Society National Committee on Prevention and Detection of Cancer, 1985 - 87
Chairman, WHO Meeting on Breast Imaging Technologies in Control of Breast Cancer, Moscow, October 1985
Chairman, WHO study group on the Russia/WHO study of breast self-examination, 1985 - 1992.
Member, Data, Safety and End-points Monitoring Committee, Minneapolis Colon Cancer Screening Study, 1986-1991.
Advisor, Committee on Diet and Health, U.S. National Academy of Sciences, 1986 - 87, Member, 1987 - 89
Member, Fellowship Committee, IARC, Lyon, 1987 - 89
Chairman, Special Advisory Panel on Ontario Gold Miners Study, Workers Compensation Board of Ontario, 1987
Member, Ad Hoc Panel on 2-4D. Ontario Ministry of the Environment, 1987
Member, Board of Directors, American College of Epidemiology, 1987-89
Member, Industrial Diseases Standards Panel, Ontario Ministry of Labour, 1987-89; Vice Chairman 1989; Acting Chairman 1990-91.
Member, Policy and Data Monitoring Group, University of Minnesota, Colon Cancer Study, 1988 - 93

Liaison Member, Committee on Dietary Guidelines Implementation, National Research Council, 1988 - 91

Chairman, Task Force on Diet Nutrition and Cancer, European School of Oncology, 1988-93

Chairman, National Workshop on Screening for Cancer of the Cervix, 1989

Chairman, Safety and Monitoring End Points Committee, CARET, Seattle, Washington, 1989 – 1996

Chairman, Advisory Committee on Cancer Control, NCIC, 1989-91, Member 1991-92

Chairman, Committee on Environmental Epidemiology, National Research Council, 1990-97

Member, Advisory Committee, Ontario Breast Screening Program, 1990 - 92

Chairman, WHO Consultation on National Cancer Control Programmes, Geneva, 1991.

Chairman, IARC Working group on evaluation of carcinogenicity to chemicals, June 1992.

Member, North Eastern Regional Cancer Centre Task Force on Environmental and Occupational Epidemiology, 1992-1996

Member, Board of Directors, Ontario Cancer Treatment and Research Foundation (OCTRF), 1993-96

Member, OCTRF Research Advisory Committee, 1993-96

Member, Health and Welfare Canada, Regulatory Review Advisory Committee, 1993.

Chairman, IARC Working group on evaluation of carcinogenicity to chemicals, June 1993.

Member, PSA Expert Panel, Ontario Ministry of Health, 1993 - 94.

Chairman, Management Committee, Canadian Childhood Cancer Control Program, 1993-96.

Member, Second WHO Consultation on National Cancer Control Programmes, Banff, 1993.

Member, WHO Expert Advisory Panel on Cancer, 1994-2004

Member, WHO Ad Hoc Committee on Health Research relating to Future Intervention Options, 1994-96

Member, Board of Directors, Cancer Care International, 1994-96

Chairman, Ontario Task Force on Primary Prevention of Cancer, 1994-95.

Member, International Scientific Advisory Committee, 17th International Cancer Congress, Rio de Janeiro Brazil, 4&5 December, 1995.

Vice-Chairman, IARC Working group on evaluation of carcinogenicity to chemicals, February 1996.

Member, Planning Committee for the NIH Consensus Development Conference on Breast Cancer Screening for Women ages 40-49, 1996-97.

Member, Safety and Data Monitoring Committee, ALTS trial (US), 1997-2000

Chairman, IARC Working group on Handbooks of Cancer Prevention, Some Non-Steroidal Anti-Inflammatory drugs, April 1997.

Chairman, Death Review Committee, US NCI Prostate, Lung, Colon and Ovary Screening trial, 1998-2004

Chairman, International Consultation on Screening for Cancer of the Cervix, Tunis, January 1999.

Member, Grants panel, World Cancer Research Fund International, 2000-2004

Chairman, Consultation on Screening for Cancer of the Cervix, (for European region of the World Health Organization), Macedonia, June 2000.

Chairman, WHO Consultation on Screening for Noncommunicable diseases, Geneva, March 2001

Chairman, WHO Consultation on Screening for Cancer of the Cervix in Middle Income Countries, Geneva, March, 2001.

Member, Scientific Committee, XVI International Epidemiology Association World Congress of Epidemiology, Montreal. 2001-2002

Member and Chairman of Epidemiology committee, Working Group for IARC Handbook of Cancer Prevention – Volume 7, Breast cancer screening, March, 2002.

Member, UICC Task Force for Strategy for National Cancer Prevention Programmes, 2002-2005.

Chairman, Endpoints Review Committee, US National Lung Screening Trial, 2002-2011.

Member and Chairman of Epidemiology committee, Working Group for IARC Handbook of Cancer Prevention – Volume 8, Fruits and vegetables, March, 2003.

Rapporteur, WHO Consultation on Strategies to improve and strengthen cancer control programmes in Europe. Geneva, November, 2003.

Member and Chairman of Epidemiology committee, Working Group for IARC Handbook of Cancer Prevention – Volume 9, Cruciferous vegetables, December, 2003.

Vice-Chairman and Chairman of Epidemiology committee, Working Group for IARC Handbook of Cancer Prevention – Volume 10, Cervix Cancer Screening, April, 2004.

Member, Council for Canadian Strategies for Cancer Control, April 2004-December, 2006

Chairman, Targets Working Group (renamed Quality Performance Assurance Action Group, 2006), Canadian Strategy for Cancer Control, 2004-07

Member, Primary Prevention Action Group, Canadian Strategy for Cancer Control, succeeded by Canadian Partnership against Cancer (2007), 2004-2010

Chairman, Behavior and Nutrition Committee, US NCI Prostate, Lung, Colon and Ovary Screening trial, 2004-2011

Chairman, Analysis, Cost-effectiveness and Modelling Committee, US NCI Prostate, Lung, Colon and Ovary Screening trial, 2004-2011

Member, National Nutrition Planning Group (Canada), 2005-07

Member, Standards Action Group, Canadian Strategy for Cancer Control, succeeded by Canadian Partnership against Cancer (2007), 2005-08

Member, WHO Cancer Technical Group, (later termed Expert Advisory Panel on Cancer) 2005-2015

Rapporteur, WHO Consultation on Strategies for Lung Cancer Prevention and Control in the Eastern Mediterranean Region, Cairo, June, 2006.

Chairman Data Safety and Monitoring Committee, British Columbia Focal screening trial, 2006-2018

Member, Working Group on Alcoholic Beverage Consumption, acetaldehyde and urethane. For Volume 96, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Lyon, France, 6-13 February, 2007.

Member, Advisory Council, Canadian Partnership against Cancer, 2007-09

Co-Chair, Cancer Risk Management Advisory Committee, Canadian Partnership against Cancer, 2008-2010

Member, Technical subcommittee of the Cancer Risk Management Advisory Committee, Canadian Partnership against Cancer, 2008-2012

Member, Action Council, Canadian Partnership against Cancer, 2008-2012

President, Comité Scientifique de l'INSPQ sur le Dépistage du Cancer Colorectal (Quebec) 2007-2008

Rapporteur, Meeting on National Cancer Control Programmes, 02-04 July, 2008, WHO Headquarters, Geneva.

Rapporteur, Meeting to adopt a Research Agenda for Prevention and Control of Non-Communicable Diseases, 25-26 August, 2008, WHO Headquarters, Geneva.

Co-Chair, Working Group for Monograph 100A, 14-21 October, 2008. International Agency for Research on Cancer, Lyon.

Member Scientific Advisory Committee, Princess Lalla Salma Association Against Cancer, Morocco 2008-2014.

Rapporteur, Intercountry meeting for the adoption of the Regional Cancer Control Strategy and developing national work plans. Eastern Mediterranean Regional Office of WHO, Cairo, 15- 18 December, 2008

Chairman Scientific Advisory Committee and member of Steering Committee, Occupational Cancer Research Centre, Ontario, 2009-2017.

Rapporteur, 2nd Meeting on a Research Agenda for Prevention and Control of Non-Communicable Diseases, 12-13 October, 2009, WHO Headquarters, Geneva.

Member, WHO Consultation – Review of International Experience in NCD Prevention and Control. WHO Headquarters Geneva, 8-10 April, 2010.

Member, Primary Prevention Advisory Group, Canadian Partnership against Cancer, 2010-2012

Co-Chair, Cancer Risk Management Steering Committee, Canadian Partnership against Cancer, 2010-2012; Chair 2012-2013, Scientific Lead 2013-2017

Chairman, Nutrition Working Group, Ontario Health Study, 2010-2012

Chairman Data Safety and Monitoring Board, Randomized Controlled Trial Evaluating Carrageenan as a Microbicide against HPV Infection, McGill University, 2010-

Member, Cancer Control Council, Canadian Partnership against Cancer, 2013-2018

Member, Working Group on Lung Cancer, Cancer Risk Management (now OncoSim), Canadian Partnership against Cancer, 2011-

Member, Working Group on Colorectal Cancer, Cancer Risk Management (now OncoSim), Canadian Partnership against Cancer, 2011-

Member, Working Group on Cervix Cancer, Cancer Risk Management (now OncoSim),

Canadian Partnership against Cancer, 2011-
Lead, Working Group on Breast Cancer, Cancer Risk Management (now OncoSim),
Canadian Partnership against Cancer, 2012-
Member Working Group for IARC Handbook of Cancer Prevention – Volume 15, Breast
cancer screening, November, 2014.
International Expert, Informal Consultation on Early Detection & Diagnosis, WHO, Geneva,
2-3 December, 2015.
Chairman, Consultative meeting on early detection and screening of priority cancers in the
WHO Eastern Mediterranean Region, Cairo, Egypt, 14-15 January 2016
Co-chair, Expert Consultation to scale up cancer care in the Eastern Mediterranean
Region of WHO, Cairo, Egypt, 27-28 November 2016.
Lead, Working Group on All cancers, OncoSim, Canadian Partnership against Cancer, 2014-
Member Technical Committee, OncoSim, Canadian Partnership against Cancer, 2017-

Consultantships

Health Insurance Plan of Greater New York, Breast Screening Study, 1980 - 1986
International Agency for Research on Cancer, Lyon, 1985 – 1987
WHO Cancer Unit, Geneva, 1986 - 96; WHO Cancer Unit, Lyon. 1996 - 1998; WHO Cancer
Programme, Geneva, 1999 -
Area Di Epidemiologia, Turin, Italy, Breast Cancer Screening Project, 1986 - 88
University of Vermont, Breast Screening Project, 1987 - 90
Pan American Health Organization, 1988 - 1996
Laboratory Centre for Disease Control, Cancer Control Program, 1992 - 1997
Early Detection Research Program, Division of Cancer Prevention, National Cancer
Institute, 1997 – 2010
Breast Screening Project, Cairo, Egypt, 2001 - 2009
Cancer Control Programme, Iraq (for Eastern Mediterranean Region of WHO), June, 2001.
Cancer Control Programme, Libya (for Eastern Mediterranean Region of WHO),
December 2001.
Cancer Care Nova Scotia, April 2002.
Cancer Control Programme, Kuwait (for Eastern Mediterranean Region of WHO),
January, 2003.
Breast Screening Project, Sana'a, the Yemen, 2006-2008
Breast Screening Project, Khartoum, Sudan, 2006
Breast Screening Project, Khurdistan (Erbil), Iraq, 2007
Breast Screening Project, Yazd City, Iran, 2007-
Cancer Control Program, Kingdom of Saudi Arabia, June, 2009
Workshop to Train Master Trainers in Breast examinations, Sultanate of Oman, December
2009.
Eastern Mediterranean Regional Office, World Health Organization, December 2013
Eastern Mediterranean Regional Office, World Health Organization, January 2015

Current Research Interests

Epidemiology of Breast Cancer, and relationship to preclinical abnormalities.

Evaluation of Screening for Cancer.

Impact of nutrition, radiation (ionizing and electrical, magnetic and radiofrequency fields) and occupation on cancer.

Environmental aspects of cancer etiology.

Control of cancer.

Editorial Functions

Editor, WHO National Cancer Control Programmes Handbook; Preliminary Edition 1992, First Edition 1995, 2nd Edition 2002.

Associate Editor, Epidemiology, International Journal of Cancer, 1999-2006, 2009-

Scientific Editor, WHO Cancer Control Technical Guide: Knowledge into Action: WHO Guide for Effective Programmes, 2005-2007

Member of Advisory Boards of: Cancer Detection and Prevention 1990-2009, Journal of the National Cancer Institute, Eastern Mediterranean Health Journal, Preventive Medicine.

Manuscript Reviewer

Acta Oncologia, American Journal of Epidemiology, American Journal of Preventive Medicine, American Journal of Public Health, Annals of Epidemiology, Annals of Internal Medicine, Biomed Central, Breast Cancer Research and Treatment, Breast Disease, British Journal of Cancer, British Medical Journal, Canadian Journal of Public Health, Canadian Medical Association Journal, Cancer, Cancer Causes and Control, Cancer Detection and Prevention, Cancer Epidemiology Biomarkers and Prevention, Cancer Prevention Research, Cancer Research, Chest, Chronic Diseases in Canada, Eastern Mediterranean Health Journal, Endocrine-Related Cancer, Epidemiology, European Journal of Cancer, European Journal of Epidemiology, International Journal of Cancer, International Journal of Epidemiology, JAMA, Journal of Clinical Oncology, Journal of General Internal Medicine, Journal of the National Cancer Institute, Journal of Public Health Policy, Journal of Thoracic Oncology, Journal of Urology, Lancet, Lancet Oncology, Lung, Nature Reviews Clinical Oncology, New England Journal of Medicine, Mayo Clinic Proceedings, Nutrition and Cancer, PLOSOne, PLOS Medicine, Preventive Medicine, Saudi Medical Journal, Science, Vaccine.

Research Grant Reviewer

Alberta Heritage Foundation for Medical Research, Anti-cancer Foundation of the Universities of South Australia, British Columbia Research Foundation, Canadian Cancer Society Research Institute, Canadian Institute for Health Research, International Union Against Cancer Fellowships Programme, Health Care Systems Research Grants, Ontario Ministry of Health, Medical Research Council, National Cancer Institute of Canada, National Health Research and Development Program, Netherlands Cancer Foundation, Saskatchewan Cancer Foundation, the Workplace Safety and Insurance Board of Ontario, the World Cancer

Research Fund.

Publications

Over 600 scientific publications on tuberculosis, cancer epidemiology and screening (list below).

Expert witness

Expert witness on tobacco and health (for the Canadian Federal Government), three suites relating to breast cancer screening (US), one class action suite on medical monitoring (US), four suites relating to cervical cancer screening (Canada), six worker's compensation appeals (Canada), a class action suite relating to DDT exposure (US) and a suite by the New Brunswick Government against the tobacco industry.

PUBLICATIONS OF Dr. A.B. MILLER

Refereed

1. Miller AB. Thiotepa in Carcinoma of Breast treated by Bilateral Adrenalectomy and Oophorectomy . Brit. Med. J. 1961; *i*, 619.
2. Hong Kong Government Tuberculosis Service/British Medical Research Council Co-operative Investigation. Drug Resistance in patients with pulmonary Tuberculosis presenting at Chest Clinics in Hong Kong. Tubercle Lond. 1964; 45: 77-95.
3. Heathfield K.W.G., Miller AB. A family showing both Dystrophia Myotonica and Spastic Paraplegia. Neurology 1965; 15: 481-485.
4. Miller AB, Fox W, Tall R. An international Co-operative Investigation into Thiacetazone (Thioacetazone) side-effects. Tubercle, Lond., 1966; 47: 33-74.
5. Miller AB, Tall R, Fox W, Lefford MJ, Mitchison DA. Primary Drug Resistance in Pulmonary Tuberculosis in Great Britain: Second National Survey, 1963. Tubercle, Lond. 1966; 47: 92-108.
6. A report to the Medical Research Council. Comparative trial of Surgery and Radiotherapy for the primary treatment of Small-celled or Oat-celled Carcinoma of the Bronchus. Lancet 1966; 2: 979-986.
7. East African/British Medical Research Council Co-operative Investigation. Tuberculosis in Kenya, a National Sampling Survey of Drug Resistance and other factors. Tubercle, Lond. 1968; 49: 136-169.
8. Hong Kong Anti-Tuberculosis Service and Government Tuberculosis Service/British Medical Research Council Investigation. A controlled comparison of Thiacetazone plus Isoniazid with PAS plus Isoniazid in Hong Kong. Tubercle Lond., 1968; 49: 243-280.

9. Briggs IL, Rochester WR, Shennan DH, Riddell RW, Fox W, Heffernan JF, Miller AB et al. Streptomycin plus thiacetazone (thioacetazone) compared with streptomycin plus PAS and with isoniazid plus thiacetazone in the treatment of pulmonary tuberculosis in Rhodesia. *Tubercle Lond.* 1968; 49:48-69.
10. Miller AB, Fox W, Tall R. Five-year follow-up of the Medical Research Council Comparative Trial of Surgery and Radiotherapy for the primary treatment of Small-celled or Oat-celled Carcinoma of the Bronchus. *Lancet* 1969; 2: 501-505.
11. East African and British Medical Research Council Cooperative Investigation. Tuberculosis in Kenya: A follow-up of a National Sampling Survey of Drug Resistance and other factors. *Tubercle Lond.* 1970; 51: 1-23.
12. Mitchison DA, Allen BW, Miller AB. Detection of Rifampicin in Urine by Simple Microbiological Assay. *Tubercle, Lond.* 1970; 51: 300-304.
13. Miller AB, Nunn AJ, Robinson DK, Ferguson GC, Fox W, Tall R. A Second International Co-operative Investigation into Thioacetazone Side-effects. I - The influence of a vitamin and antihistamine supplement. *Bull. W.H.O.* 1970; 43: 107-125.
14. A report by a Medical Research Council Working Party (AB Miller, secretary) Study of Cytotoxic Chemotherapy as an Adjuvant to Surgery in Carcinoma of the Bronchus. *British Medical Journal* 1971; 2: 421-428.
15. Singapore Tuberculosis Services/Brompton Hospital/British Medical Research Council Investigation. A controlled Clinical Trial of the Role of Thiacetazone-containing Regimens in the Treatment of Pulmonary Tuberculosis in Singapore. *Tubercle, Lond.* 1971; 52: 88-116.
16. Ferguson GC, Nunn AJ, Fox W, Miller AB, Robinson DK, Tall R. A Second International Co-operative Investigation into thiacetazone Side-effects: Rashes on Two Thiacetazone-containing Regimens. *Tubercle, Lond.* 1971; 52: 166-181.
17. Oswald NC, Hinson KF, Canti G, Miller AB. The Diagnosis of Primary Lung Cancer with Special Reference to Sputum Cytology. *Thorax* 1971; 26: 623-7.
18. Miller AB, Nunn AJ, Robinson DK, Fox W, Somasundaram PR, Tall R. A Second International Co-operative Investigation into Thioacetzone Side-effects. II - The Geographical Incidence of Side-effects. *Bull. W.H.O.* 1972; 47: 211-227.
19. Hong Kong Tuberculosis Services/British Medical Research Council Investigation. A Study in Hong Kong to evaluate the role of pretreatment susceptibility tests in the selection of regimens of chemotherapy for pulmonary tuberculosis. *Am. Rev. Resp. Dis.* 1972; 106: 1-22.
20. A joint National Cancer Institute of Canada/American Cancer Society Investigation. A Collaborative Study of the Test of Carcinoembryonic Antigen in Carcinoma of the Colon and Rectum. *CMA Journal* 1972; 107: 25-33.
21. Miller AB. Screening for Lung Cancer. *Journal C.P.H.A.* 1973; 64:S32.

22. Miller AB. The Epidemiology of Oral Cancer. *Journal Canadian Dental Association* 1974; 40:211-217.
23. Leger JL, Naimark AP, Beique R, McFarlane DV, Miller S, Miller AB. Report of the "Ad Hoc" committee on mammography. *J. Canad. Assoc. Rad.* 1974; 25:3-21.
24. Miller AB. The Joint National Cancer Institute of Canada/American Cancer Society Study of a Test for Carcinoembryonic Antigen (CEA). *Cancer* 1974; 34:932-935.
25. Hinson KFW, Miller AB, Tall R. An Assessment of the World Health Organization Classification of the Histological Typing of Lung Tumors applied to biopsy and resected material. *Cancer*, 1975; 35: 399-405.
26. Miller AB, Lindsay J, Hill GB. Mortality from Cancer of the Uterus in Canada and its Relationship to Screening for Cancer of the Cervix. *Int. J. Cancer* 1976; 17: 602-612.
27. Task Force appointed by the Conference of Deputy Ministers of Health, Cervical Cancer Screening Programmes. *Canadian Medical Association Journal* 1976; 114: 1003-1033.
28. Miller AB. Recent Trends of Lung Cancer Mortality in Canada. *CMA Journal* 1977; 116: 28-30.
29. Band PR, Beck IT, Dinner PJ, Miller AB. Two-year follow-up study of patients with known serum concentrations of carcinoembryonic antigen. *CMA Journal* 1977; 117: 657-658.
30. Howe GR, Burch JD, Miller AB, Morrison B, Gordon P, Weldon L, Chambers LW, Fodor G, Winsor GM. Artificial sweeteners and human bladder cancer, *Lancet* 1977; ii: 578-581.
31. Miller AB. Asbestos fibre dust and gastro-intestinal malignancies. (Review). *J. Chron Dis* 1978; 31: 23-33.
32. Morgan RW, Jain M, Miller AB, Choi NW, Matthews V, Munan L, Burch JD, Feather J, Howe GR, Kelly A. A comparison of Dietary Methods in Epidemiologic Studies. *Am J Epidemiol* 1978; 107: 488-498.
33. Miller AB, Kelly A, Choi NW, Matthews V, Morgan RW, Munan L, Burch JD, Feather J, Howe GR, Jain M. A Study of Diet and Breast Cancer. *Am J Epidemiol* 1978; 107: 499-509.
34. Choi NW, Howe GR, Miller AB, Matthews V, Morgan RW, Munan L, Burch JD, Feather J, Jain M, Kelly A. An Epidemiologic Study of Breast Cancer. *Am J Epidemiol* 1978; 107: 510-521.
35. Miller AB. An overview of hormone-associated cancers. *Cancer Research* 1978; 38: 3985-3990.

36. Sherman GJ, Howe GR, Miller AB, Rosenstein M. Organ dose per unit exposure resulting from fluoroscopy for artificial pneumothorax. *Health Physics* 1978; 35: 259-269.
37. Report of the Working Group to review the National Cancer Institute - American Cancer Society Breast Cancer Detection Demonstration Projects (Beahrs, Shapiro, Smart, et al.) *JNCI* 1979; 62: 641-709.
38. Klaassen DJ, Boyes DA, Gerulath A, Levitt M, Miller AB, Pearson JG. Preliminary report of a clinical trial of the treatment of patients with Advanced Stage III and IV Ovarian Cancer with Melphalan, 5 fluorouracil and methotrexate in combination and sequentially. *Cancer Tr. Reps.* 1979; 63: 289-295.
39. Miller AB, Taylor HE, Baker MA et al. Oral administration of BCG as an adjuvant to surgical treatment of carcinoma of the bronchus. *CMA Journal* 1979; 121: 45-54.
40. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RM, White DF, Miller AB. The Chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. *New Engl. J. Med.* 1979; 301: 743-748.
41. Howe GR, Lindsay J, Coppock E, Miller AB. Isoniazid exposure in relation to Cancer Incidence and mortality in a cohort of tuberculosis patients. *Int J Epidemiol*, 1979; 8: 305-312.
42. Jain M, Howe GR, Johnson KC, Miller AB. Evaluation of a diet history questionnaire for epidemiologic studies. *Am J Epidemiol.* 1980; 111: 212-219.
43. Magnus K, Miller AB. Controlled prophylactic trials in Cancer. *J. Natl. Cancer Inst.* 1980; 64: 693-699.
44. Howe GR, Burch JD, Miller AB et al. Tobacco Use, Occupation, Coffee, Various nutrients and Bladder Cancer. *J Natl Cancer Inst* 1980; 64: 701-713.
45. Jacques J, Hill DP, Shier KJ, Jindani A, Miller AB. Appraisal of the World Health Organization Classification of lung tumours. *CMA Journal* 1980; 122: 897-901.
46. Miller AB. The epidemiology of malignant disease. A Basis for Public Policy. *Health Commun Informatics.* 1980; 6: 283-294.
47. Howe GR, Lindsay J, Miller AB. Cancer incidence and mortality in relation to occupation in 700,000 members of the Canadian labour force. *Cancer Detection and Prevention* 1980; 3: 487-497.
48. Miller AB, Klaassen DJ, Boyes DA et al. Combination v. Sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer. *CMA Journal* 1980; 123: 365-371.
49. Miller AB, Barclay THC, Choi NW et al. A study of cancer, parity and age at first pregnancy. *J. Chron. Dis.* 1980; 33:595-605.

50. Miller AB, Bulbrook RD. Epidemiology and etiology of breast cancer. *New Eng. J. Med.* 1980; 303: 1246-1248.
51. Jain M, Cook GM, Davis MG, Howe GR, Miller AB. A case-control study of diet and colo-rectal cancer. *Int. J. Cancer* 1980; 26: 757-768.
52. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. *Cancer* 1981; 47: 207-214.
53. Howe GR, Sherman GJ, Semincew RM, Miller AB. Estimated benefits and risks of screening for breast cancer. *CMA Journal* 1981; 124: 399-403.
54. Burch, J.D., Howe, G.R. and Miller, A.B. Breast Cancer in relation to weight in women age 65 years and over. *CMA Journal* 1981; 124: 1326-1327.
55. Miller, A.B., Visentin, T. and Howe, G.R. The effect of hysterectomies and screening on mortality from cancer of the uterus in Canada. *Int. J. Cancer* 1981; 27: 651-657.
56. Burch, J.D., Howe, G.R., Miller, A.B. and Semenciw, R. Tobacco, alcohol, asbestos and nickel in the etiology of cancer of the larynx: a case-control study. *J Natl. Cancer Inst.* 1981; 67: 1219-1224.
57. Miller, A.B., Howe, G.R. and Wall, C. The national study of breast cancer screening. *Clinical and Investigative Medicine*, 1981; 4: 227-258.
58. Yu, S.Z., Miller, A.B, Sherman G.J. Optimizing the age, number of tests, and test interval for cervical screening in Canada. *J. Epidemiol. & Commun. Hlth.* 1982; 36: 1-10.
59. Miller, A.B., Bulbrook, R.D. Screening, detection and diagnosis of breast cancer. *Lancet* 1982; 1: 1109-1111.
60. Boyes, D.A., Morrison, B., Knox E.G., Draper, G, Miller, A.B. A cohort study of cervical cancer screening in British Columbia. *Clinical Investigative Medicine* 1982; 5: 1-29.
61. Boyd, N.F., Wolfson, C., Moskowitz, M., Carlile, T., Petitclerc, M., Ferri, H.A., Fishell, E., Gregoire, A., Kierman, M., Longley, J.D., Simor, I.S., Miller, A.B. Observer variation in the interpretation of xeromammograms. *J.N.C.I.* 1982; 68: 357-363.
62. Walton, R.J., Allen, H.H., Anderson, G.H., Boyes, D.A., Blanchet, M., Carmichael, J., Gellman, D.D., Hill, G.B., Miller, A.B., Thomson, D.W. and Kassierer, E. Cervical Cancer Screening Programmes: Summary of the 1982 Canadian Task Force Report. *CMA Journal* 1982; 127: 581-589.
63. Miller, A.B. Risk Factors from Geographic Epidemiology for Gastro-Intestinal Cancer. *Cancer* 1982; 50: 2533-2540.

64. Jain, M.G., Harrison, L., Howe, G.R., Miller, A.B. Evaluation of a self-administered dietary questionnaire for use in a cohort study. *Am. J. Clin. Nutrition.* 1982; 36: 931-935.
65. Miller, A.B., Howe, G.R., Jain, M., Craib, K.J.P., Harrison L. Food items and food groups as risk factors in a case-control study of diet and colo-rectal cancer. *Int. J. Cancer* 1983; 32: 155-161.
66. Prorok PC, Chamberlain J, Day NE, Hakama M, Miller AB. UICC Workshop on the evaluation of screening programmes for cancer. *Int. J. Cancer* 1984; 34: 1-4.
67. Miller, A.B. Hospital or population controls. An unanswered question. *J. Chron. Dis.* 1984; 37: 337-338.
68. Miller, A.B. Screening for cancer of the cervix: Implications for public health policy. *Journal Public Health Policy.* 1985; 6: 43-57.
69. Schechter, M.T., Miller, A.B., and Howe, G.R. Cigarette smoking and breast cancer: A case control-study of screening program participants. *Am. J. Epidemiol,* 1985; 121: 479-487.
70. Miller, A.B., Chamberlain, J., Tsechkovski, M. Self-examination in the early detection of breast cancer. *J. Chron. Dis.* 1985; 38: 527-540.
71. Goldenberg, G.J., Brandes, L.J., Lan, W.H., Miller, A.B., Wall, C. and Ho, J.C. Cooperative trial of immunotherapy for nasopharyngeal carcinoma with transfer factor from donors with Epstein-Barr virus antibody activity. *Cancer Treat. Repts.* 1985; 69: 761-767.
72. Klaassen, D., Starrweld, A., Shelly, W., Miller, A.B., Boyes, D., Gerulath, A, Levett, M. External beam pelvic radiotherapy plus intraperitoneal radioactive chronic phosphate in early stage ovarian cancer: A toxic combination. A National Cancer Institute of Canada Clinical Trials Group Report. *Int. J. Radiation Oncology Biol. Phys.* 1985; 11: 1801-1804.
73. Howe, G.R, Craib K.J.P, Miller, A.B. Age at first pregnancy and risk of colorectal cancer. A case-control study. *J. Natl. Cancer Inst.*1985; 74: 1155-1159.
74. Miller, A.B. Nutrition and Cancer. An epidemiological overview. *J. Nutr. Growth and Cancer* 1985; 2: 159-171.
75. Risch, H.A., Jain, M., Choi, N.W., Fodor, J.G., Pfeiffer, C.J., Howe, G.R., Harrison, L.W., Craib, K.J.P., Miller, A.B. Dietary factors and the incidence of cancer of the stomach. *Am. J. Epidemiol.* 1985; 122: 947-959.
76. Hakama, M., Chamberlain, J., Day, N.E., Miller, A.B. and Prorok, P.C. Evaluation of screening programmes for gynecological cancer. *Br. J. Cancer* 1985; 52: 669-673.

77. Schechter, M.T., Miller, A.B., Baines, C.J., Howe, G.R. Selection of women at high risk of breast cancer for initial screening. *J. Chron. Dis.* 1986; 39: 253-260.
78. Miller, A.B., Bulbrook, R.D. UICC Multidisciplinary project on breast cancer: the epidemiology, aetiology and prevention of breast cancer. *Int. J. Cancer* 1986; 37: 173-177.
79. Newman, S.C., Miller, A.B., Howe, G.R. A study of the effect of weight and dietary fat on breast cancer survival time. *Am. J. Epidemiol.* 1986; 123: 767-774.
80. Baines, C.J., Miller, A.B., Wall, C., McFarlane, D.V., et al. Sensitivity and specificity of first screen mammography in the Canadian National Breast Screening Study: A preliminary report from five centers. *Radiology* 1986; 160: 295-298.
81. Boyd, N.F., Wolfson, C., Moskowitz, M., Miller, A.B. Observer variation in the classification of mammographic parenchymal patterns. *J. Chron. Dis.* 1986; 39: 465-472.
82. Chamberlain, J., Day, N.E., Hakama, M., Miller, A.B., Prorok, P.C. UICC workshop of the project on evaluation of screening programmes for gastrointestinal cancer. *Int. J. Cancer* 1986; 37: 329-334.
83. Howe, G.R., Nair, R.C., Newcombe, H.B., Miller, A.B., Abbatt, J.D. Lung cancer mortality (1950-80) in relation to radon daughter exposure in a cohort of workers at the Eldorado Beaverlodge uranium mine. *J. Natl. Cancer Inst.* 1986; 77:357-362.
84. Day, N.E., Baines, C.J., Chamberlain, J., Hakama, M., Miller, A.B., Prorok, P. UICC project on screening for cancer: report of the workshop on screening for breast cancer. *Int. J. Cancer* 1986; 38:303-308.
85. Miller, A.B. Screening for cancer: issues and future directions. *J. Chron.Dis.* 1986; 39: 1067-1077.
86. Burch, J.D., Craib, K.J.P. Choi, B.C.K., Miller, A.B., Risch, H.A., Howe, G.R. An exploratory case-control study of brain tumors in adults. *J. Natl. Cancer Inst.* 1987; 78: 601-609.
87. Miller, A.B., Tsechkovski, M. Imaging technologies in breast cancer control: summary of a report of a World Health Organization meeting. *Am J Roentgenol.* 1987; 48: 1093-1094.
88. Howe, G.R., Nair, R.C., Newcombe, H.B., Miller, A.B., Burch, J.D., Abbatt, J.D. Lung cancer mortality (1950-80) in relation to radon daughter exposure in a cohort of workers at the Eldorado Port Radium uranium mine: possible modification of risk by exposure rate. *JNCI* 1987; 79: 1255-1260.
89. Pron GE, Burch JD, Howe GR, Miller AB. The reliability of passive smoking histories reported in a case-control study of lung cancer. *Am J Epidemiol.* 1988; 127: 267-273.

90. Risch, H.A., Burch, J.D., Miller, A.B. et al. Dietary factors and the incidence of cancer of the bladder in Canada. *Am J Epidemiol* 1988; 127: 1179-1191.
91. Risch, H.A., Burch, J.D., Miller, A.B., et al. Occupational factors and the incidence of cancer of the bladder in Canada. *Br J Ind. Med.* 1988; 45: 361-367.
92. Risch, H.A., Weiss, N.S., Clarke, E.A., Miller, A.B. Risk factors for spontaneous abortion and its recurrence. *Am. J. Epidemiol* 1988; 128: 420-430.
93. Miller, A.B., The ethics, the risk and the benefits of screening. *Biomed and Pharmacother.* 1988; 42: 439-442.
94. Baines, C.J., McFarlane, D.V., Miller, A.B., et al Sensitivity and specificity of first screen mammography in 15 NBSS centres. *J Can Assoc Radiol* 1988; 39: 273-276.
95. Miller, A.B. Screening for cancer: State of the art and prospects for the future. *World J. Surg.* 1989; 13: 79-83.
96. Baines, C.J., Miller, A.B., Bassett, A.A. Physical examination. Its role as a single screening modality in the Canadian National Breast Screening Study. *Cancer* 1989; 63: 1816-1822.
97. Jain, M., Howe, G.R., Harrison, L. and Miller, A.B. A study of repeatability of dietary data over a seven-year period. *Am J Epidemiol* 1989; 129: 422-429.
98. Schechter, M.T., Miller, A.B., Howe, G.R. et al Cigarette smoking and breast cancer: case control studies of prevalent and incident cancer in the Canadian National Breast Screening Study. *Am J Epidemiol* 1989;130: 213-220.
99. Miller, A.B., Howe, G.R., Sherman, G.J. et al Mortality from breast cancer after radiation during fluoroscopic examination in patients being treated for tuberculosis. *New Engl. J. Med.* 1989; 321: 1285-1289.
100. Burch, J.D., Rohan T.E., Howe, G.R., Risch, H.A., Hill, G.B., Steele R, Miller, A.B. Risk of bladder cancer by source and type of tobacco exposure. A case-control study. *Int J Cancer* 1989; 44: 622-628.
101. Miller, A.B. Mammography: A critical evaluation of its role in breast cancer screening, especially in developing countries. *J Publ Health Policy* 1989; 10: 486-498.
102. Miller, A.B., Prentice, R., Tibshirani, R., Boyd, N., Corey, P. Terry Fox Cancer Research Workshop on Prevention Trials. *Int J Cancer* 1989; 44: 767-769.
103. Baines, C.J., Christen, A. et al and Miller, A.B. The National Breast Screening Study: pre-recruitment sources of awareness in participants. *Can J Publ Hlth.* 1989; 80: 221-225.
104. Jain, M., Burch, J.D., Howe, G.R., Risch, H.A., Miller, A.B. Dietary factors and risk of lung cancer: results from a case-control study, Toronto, 1981-1985. *Int J Cancer* 1990; 45: 287-293.

105. Howe, G.R., Jain, M., Miller, A.B. Dietary factors and risk of pancreatic cancer: results of a Canadian population-based study. *Int. J. Cancer* 1990; 45: 604-608.
106. Baines, C.J., McFarlane, D.V., Miller, A.B. The role of the reference radiologist. Estimates of inter-observer agreement and potential delay in cancer detection in the National Breast Screening Study. *Investigative Radiology* 1990; 25: 971-976.
107. Perucci, C.A., Rapiti, E., Davoli, M., Lagorio, S., Area, M., Miller, A.B. Rome women's screening study: Knowledge, attitudes and practices of women regarding screening for breast and cervical cancer. *Tumori* 1990; 76: 365-369.
108. Baines, C.J., Miller, A.B., Kopans, D.B., Moskowitz, M., Sanders, D.E., Sickles, E.A., To, To., Wall, C. Canadian National Breast Screening Study: Assessment of technical quality of external review. *Am J Roentgenology* 1990; 155: 743-74.
109. Adami H.O., Adams G., Boyle P., Ewertzs M., Lee N.C., Lund E., Miller A.B., Olsson H., Steel M., Trichopoulos D., Tulinius H. Breast-cancer etiology. *Int J Cancer* 1990; Supplement 5, 22-39.
110. Rutqvist, L.E., Miller, A.B., Andersson I., Hakama, M., Hakulinen, T., Sigfusson, B.F., Tabar, L. Reduced breast cancer mortality with mammography screening. An assessment of currently available data. *Int J Cancer* 1990; Supplement 5, 76-84.
111. Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC. Report on a workshop of the UICC Project on evaluation of screening for cancer. *Int J Cancer* 1990; 46: 761-769.
112. Ugnat AM, Miller AB, Wigle DT. Effects of residential exposure to environmental tobacco smoke on Canadian children. *Can J Pub Hlth* 1990; 81: 345-349.
113. Miller, A.B. Risk/Benefit considerations of antiestrogen/estrogen therapy in healthy postmenopausal women. *Prev. Med.* 1991; 20: 79-85.
114. L'Abbe K., Howe G.R., Burch J.D., Miller A.B., et al. Radon exposure, cigarette smoking, and other mining experience in the Beaverlodge Uranium miners cohort. *Hlth Physics* 1991; 60: 489-495.
115. Howe GR, Rohan T, Decarli A, Iscovich J, Kaldor J, Katsouyanni K, Marubini E, Miller AB, Riboli E, Toniolo P, Trichopoulos D. The association between alcohol and breast cancer risk: evidence from the combined analysis of six dietary case-control studies. *Int J Cancer* 1991; 47: 707-710.
116. Miller A.B. Role of early diagnosis and screening; biomarkers. *Cancer Det. Prev.* 1991; 15:21-26.
117. Howe G.R., Friedenreich C.M., Jain M., Miller A.B. A cohort study of fat intake and risk of breast cancer. *J Natl Cancer Inst.* 1991; 83: 336-340.
118. Miller A.B. Epidemiological approaches to primary and secondary prevention of cancer. *J Cancer Res Clin Oncol.* 1991; 117: 177-185.

119. Miller A.B. Is routine mammography screening appropriate for women 40-49 years of age? *Am. J Prev. Med.* 1991; 7: 55-62.
120. Jain M, Howe G.R., St. Louis P., Miller A.B. Coffee and alcohol as determinants of risk of pancreas cancer. A case-control study from Toronto. *Int J Cancer* 1991; 47: 384-389.
121. Howe G.R., Jain M., Burch J.D., Miller A.B. Cigarette smoking and cancer of the pancreas: Evidence from a population-based case-control study in Toronto, Canada. *Int J Cancer* 1991; 47: 323-328.
122. Miller A.B., Baines C.J., Turnbull C. The role of the nurse-examiner in the National Breast Screening Study. *Can J Publ Hlth* 1991; 82: 162-167.
123. Narod S.A., Thompson D.W., Jain M., Wall C., Green L.M., Miller A.B. Dysplasia and the Natural History of Cervical Cancer. Early results of the Toronto cohort study. *Eur J Cancer* 1991; 27: 1411-1416.
124. Hogan D.J., To T., Wilson E.R., Miller A.B. et al. A study of acne treatments as risk factors for skin cancer of the head and neck. *Br J Dermatol* 1991; 125: 343-348.
125. Holowaty E.J., Risch H.A., Miller A.B., Burch J.D. Lung cancer in women in the Niagara region Ontario: a case-control study. *Can J Pub Hlth* 1991; 82: 302-309.
126. Yelle D, Bergsagel D, Basco V, Brown T, Bush R, Gillies J, Israels L, Miller A, Rideout D, Whitelaw D, et al. Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada Clinical Trials Group multicenter clinical trial. *J Clin Oncol* 1991; 9(11):1983-1993.
127. Friedenreich CM, Howe GR, Miller AB. An investigation of recall bias in the reporting of past food intake among breast cancer cases and controls. *Ann Epidemiol* 1991; 1: 439-435.
128. Friedenreich CM, Howe GR, Miller AB. The effect of recall bias on the association of calorie-providing nutrients and breast cancer. *Epidemiol* 1991; 2: 424-429.
129. Devitt J.E., To T., Miller A.B. Risk of breast cancer in women with breast cysts. *Can Med Assoc J* 1992; 147: 45-49.
130. Hoel D.G., Davis D.L., Miller A.B. et al. Trends in cancer mortality in 15 industrialized countries, 1969-1986. *J Natl Cancer Inst* 1992; 84: 313-320.
131. Howe GR, Ghadirian P, de Mesquita HBB, Zatonski WA, Baghurst PA, Miller AB et al. A collaborative case-control study of nutrient intake and pancreatic cancer within the Search programme. *Int J Cancer* 1992; 51: 365-372.
132. Yu H, Rohan TE, Cook MG, Howe GR and Miller AB. Risk factors for fibroadenoma: a case-control study in Australia. *Am J Epidemiol* 1992; 135: 247-258.

133. Miller AB, Baines CJ, To T, Wall C et al. Canadian national breast screening study: 1. Breast cancer detection and death rates among women age 40-49 years. *Can Med Assoc J* 1992; 147: 1459-1476.
134. Miller AB, Baines CJ, To T, Wall C et al. Canadian national breast screening study: 2. Breast cancer detection and death rates among women age 50-59 years. *Can Med Assoc J* 1992; 147: 1477-1488.
135. Soskolne CL, Jhangri GS, Siemiatycki J...Miller AB et al. Occupational exposure to sulfuric acid in Southern Ontario, Canada, in association with laryngeal cancer. *Scand J work, environ hlth*, 1992; 18: 225-232.
136. Howe GR, Benito E, Castelleto R, Cornée J, Estève J, Gallagher RP, Iscovich JM, Deng-ao J, Kaaks R, Kune GA, Kune S, L'Abbé KA et al. Dietary intake of fiber and decreased risk of cancers of the colon and rectum: evidence from the combined analysis of 13 case-control studies. *J Natl Cancer Inst* 1992; 84: 1887-1896.
137. Miller AB. Perspective: epidemiologic research. *Chronic Diseases in Canada* 1992; 13: S38-S40.
138. Miller AB. Mammography: reviewing the evidence. *Can Fam Physician* 1993; 39: 85-90.
139. Holowaty PH, Miller AB, Baines CJ, Risch H. Canadian National Breast Screening Study: First screen results as predictors of future breast cancer risk. *Cancer Epidemiology, Biomarkers & Prevention*, 1993; 2: 11-19.
140. Miller AB. Canadian National Breast Screening Study: public health implications. *Can J Pub Hlth* 1993; 84: 14-16.
141. Friedenreich CM, Howe GR, Miller AB, Jain MG. A cohort study of alcohol consumption and risk of breast cancer. *Am J Epidemiol* 1993; 137: 512-520.
142. Risch HA, Howe GR, Jain M, Burch JD, Holowaty EJ, Miller AB. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. *Am J Epidemiol*; 1993; 138: 281-293.
143. Friedenreich CM, Howe GR, Miller AB. Recall bias in the association of micronutrient intake and breast cancer. *J Clin Epidemiol* 1993; 46: 1009-1017.
144. Rohan TE, Howe GR, Friedenreich CM, Jain M, Miller AB. Dietary fiber, vitamin A, C, and E, and risk of breast cancer: a cohort study. *Cancer Causes and Control* 1993; 4: 29-37.
145. Russian Federation/World Health Organization Study. Study of the role of breast self-examination in the reduction of mortality from breast cancer. *Eur J Cancer* 1993; 29A: 2039-2046.
146. Miller AB. What is the role of early detection and screening in cancer control? *J Publ Hlth Policy* 1993; 14: 403-412.

147. Theriault G, Goldberg M, Miller AB et al. Cancer risks associated with occupational exposure to magnetic fields among electric utility workers in Ontario and Quebec, Canada, and France: 1970-1989. *Am J Epidemiol* 1994; 139: 550-572.
148. Miller AB. Mammography screening guidelines for women 40 to 49 and over 65 years old. *Ann Epidemiol* 1994; 4: 96-101.
149. Miller AB, Berrino F, Hill M et al. Diet in the aetiology of cancer: a review. *Eur J Cancer* 1994; 30A: 207-220.
150. Gastrin G, Miller AB, To T, Aronson KJ, Wall C, Hakama M, Louivouri K, Pukkala E. Incidence and mortality from breast cancer in the Mama program for breast screening in Finland, 1973-1986. *Cancer* 1994; 73: 2168-2174.
151. Miller AB. Screening for cancer: Is it time for a paradigm shift? *Annals Royal College of Physicians and Surgeons of Canada* 1994; 27: 353-355.
152. Jain M, Miller AB, To T. Premorbid diet and the prognosis of women with breast cancer. *J Natl Cancer Inst* 1994; 86: 1390-1397.
153. Jain M, Miller AB. Pre-morbid body size and the prognosis of women with breast cancer. *Int J Cancer* 1994; 59: 363-368.
154. Gibbons L, Mao Y, Levy IG, Miller AB. The Canadian Childhood Cancer Control Program. *Can Med Ass J* 1994; 151: 1704-1709
155. Harvey BJ, Miller AB, Baines CJ, Corey PN. The effect of consulting publicly available sources to locate subjects in a study of recall bias. *Amer Assoc Adv of Sci.* 1994; 138.
156. Ponten J, Adami HO, Bergstrom R, Dillner J, Friberg LG, Gustafsson L, Miller AB, Parkin DM, Sparen P, Trichopoulos D. Strategies for global control of cervical cancer. *Int J Cancer* 1995; 60: 1-26.
157. Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, Lockwood GA, Trichler DL, Yaffe MJ. Quantitative classification of mammographic densities and breast cancer risk: Results from the Canadian National Breast Screening Study. *J Natl Cancer Inst* 1995; 87: 670-675.
158. Davis DL, Miller AB, Love SM. Should screening mammography be performed for women 40-49 years of age? *Medical Imaging International*; July-August 1995: 14-19.
159. Miller AB. Primary prevention of cancer: needs and opportunities for research. *Environ Health Perspect* 1995; 103 (Suppl 8): 313-317.
160. Miller AB. Perspectives on cancer prevention. *Risk Analysis* 1995; 15: 655-660.
161. Hunter DJ, Spiegelman D, Adami HO.....Miller AB et al. Cohort studies of fat intake and the risk of breast cancer - a pooled analysis. *N Engl J Med* 1996; 334: 356-361.

162. Busetti MC, Miller AB, To T, Rohan TE. Risk factors for breast cancer mortality among the National Breast Screening Study of Canada participants. *Cancer Detection and Prevention* 1996; 20: 122-129.
163. Miller AB, To T, Agnew DA, Wall C, Green LM. Leukemia following occupational exposure to 60-Hz electric and magnetic fields among Ontario electric utility workers. *Am J Epidemiol* 1996; 144: 150-160.
164. Boyle P, Maisonneuve P, Bueno de Mesquita B.....Miller AB et al. Cigarette smoking and pancreas cancer: a case control study of the SEARCH programme of the IARC. *Int J Cancer* 1996; 67: 63-71.
165. Collaborative Group on Hormonal Factors in Breast Cancer (A.B.Miller, member). Breast cancer and hormonal contraception. *Lancet* 1996; 347: 1713-1727.
166. Hunter DJ, Spiegelman D, Adami HO.....Miller AB et al. Non-dietary factors as risk factors for breast cancer, and as effect modifiers of the association of fat intake and risk of breast cancer. *Cancer Causes and Control* 1997; 8: 49-56.
167. Howe GR, Aronson KJ, Benito E.....Miller AB et al. The relationship between dietary fat intake and risk of colorectal cancer: evidence from the combined analysis of 13 case-control studies. *Cancer Causes and Control* 1997; 8: 215-228.
168. Green LM, Dodds L, Miller AB et al. Risk of congenital anomalies in children of parents occupationally exposed to low level ionising radiation. *Occupational and Environmental Med.* 1997; 54: 629-635.
169. Elovainio L, Nieminen P, Miller AB. Impact of cancer screening on women's health. *Int J. Gynec Obstet.* 1997; 58: 137-147.
170. Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study: Update on breast cancer mortality. *J Natl Cancer Inst. Monographs* 1997; 22: 37-41.
171. Baines CJ, Miller AB. Mammography versus clinical examination of the breasts. *J Natl Cancer Inst. Monographs* 1997; 22: 125-129.
172. Harvey BJ, Miller AB, Baines CJ, Corey PN. Effect of breast self-examination techniques on the risk of death from breast cancer. *Can Med Assoc J* 1997; 157:1205-1212.
173. Collaborative Group on Hormonal Factors in Breast Cancer (A.B.Miller, member). Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 53705 women with breast cancer and 108411 women without breast cancer. *Lancet* 1997; 350: 1047-1059.
174. Rohan TE, Jain M, Miller AB. A case-cohort study of diet and risk of benign proliferative epithelial disorders of the breast (Canada). *Cancer Causes and Control* 1998; 1: 19-27.
175. Smith-Warner SA, Speigelman D, Yuan SS,Miller AB et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. *JAMA* 1998; 279: 535-540.

176. Villeneuve PJ, Agnew DA, Corey PN, Miller AB. Alternate indices of electric and magnetic field exposures among Ontario electrical utility workers. *Bioelectromagnetics* 1998; 19: 140-151.
177. Rohan TE, Hartwick W, Miller AB, Kandel RA. Immunohistochemical detection of cerbB-2 and p53 in benign breast disease and breast cancer risk. *J Natl Cancer Inst* 1998; 90: 1262-1269.
178. Rohan TE, Jain M, Miller AB. Alcohol consumption and risk of benign proliferative epithelial disorders of the breast: a case-cohort study. *Pub Hlth Nutr* 1998; 1: 139-145.
179. Holowaty P, Miller AB, Rohan T, To T. The natural history of dysplasia of the uterine cervix. *J Natl Cancer Inst* 1999; 91: 252-258.
180. Rohan TE, Miller AB. Hormone replacement therapy and risk of benign epithelial disorders of the breast. *Eur J Cancer Prevention* 1999; 8: 123-130.
181. The International Prostate Screening Trial Evaluation Group (Miller AB, Chairman of writing committee). Rationale for randomised trials of prostate cancer screening. *Eur J Cancer* 1999; 35: 262-271.
182. Musgrave MA, Aronson KJ, Narod S, Hanna W, Miller AB, McCreedy DR. Breast cancer and organochlorines: a marker for susceptibility? *Surgical Oncology* 1999; 7: 1-4.
183. Rohan TE, Miller AB. A cohort study of oral contraceptives and risk of benign breast disease. *Int J Cancer* 1999; 82: 191-196.
184. Green LM, Miller AB, Villeneuve P, Agnew DA, Greenberg ML, Li J, Donnelly KE. A case-control study of childhood leukemia in Southern Ontario, Canada, and exposure to magnetic fields in residences. *Int J Cancer* 1999; 82: 161-170.
185. Green LM, Miller AB, Agnew DA, Greenberg ML, Li J, Villeneuve PJ, Tibshirani R. Childhood leukemia and personal monitoring of residential exposures to electric and magnetic fields in Ontario Canada. *Cancer Causes and Control* 1999; 10: 233-243.
186. Miller AB. The brave new world – What can we realistically expect to achieve through cancer control early in the new millenium? *Chronic Diseases in Canada* 1999; 20: 139-150.
187. Rohan TE, Miller AB. A cohort study of cigarette smoking and risk of fibroadenoma. *J Epidemiol Biostat.* 1999; 4: 297-302.
188. Aronson KJ, Miller AB, Woolcott CG, Sterns EE, McCreedy DR, Lickley LA, Fish EB, Hiraki GY, Holloway C, Ross T, Hanna WM, SenGupta SK, Weber J-P. Breast adipose tissue concentrations of polychlorinated biphenyls and other organochlorines and breast cancer risk. *Cancer Epid Biom. Prev.* 2000; 9: 55-63
189. Rohan TE, Jain MG, Howe GR, Miller AB. Dietary folate consumption and breast cancer risk. *J Natl Cancer Inst* 2000; 92: 266-269.

190. Rohan TE, Jain M, Rehm JT, Ashley MJ, Bondy SJ, Ferrence RG, Cohen J, Miller AB. Cigarette smoking and risk of death from colorectal cancer in women. *Colorectal Disease* 2000; 2: 298-303.
191. Villeneuve PJ, Agnew DA, Miller AB, Corey PN. Non-Hodgkin's lymphoma among electric utility workers in Ontario: the evaluation of alternate indices of exposure to 60 Hz electric and magnetic fields. *Occup Environ Med* 2000; 57: 249-257.
192. Miller AB, Nazeer S, Fonn S, Brandup-Lukanow A, Rehman R, Cronje H, Sankaranarayanan R, Koroltchouk V, Syrjanen K, Singer A, Onsrud M; on behalf of the participants. Report on consensus conference on cervical cancer screening and management. *Int J Cancer* 2000; 86: 440-447.
193. Villeneuve PJ, Agnew DA, Miller AB, Corey PN, Purdham JT. Leukemia in electric utility workers: The evaluation of alternative indices of exposure to 60 Hz electric and magnetic fields. *Am J Ind Med* 2000; 37: 607-617.
194. Boyd NF, Jensen HM, Cooke G, Lee Han H, Lockwood GA, Miller AB. Mammographic densities and the prevalence and incidence of histological types of benign breast disease. *Eur J Cancer Prevention* 2000; 9: 15-24.
195. Rohan TE, Jain M, Howe GR, Miller AB. Alcohol consumption and risk of breast cancer: a cohort study. *Cancer Causes and Control* 2000; 11: 239-247.
196. Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women age 50-59 years. *J Natl Cancer Inst* 2000; 92: 1490-1499.
197. Van den Brandt PA, Spiegelman D, Yuan S-S, Adami HO.....Miller AB..... Hunter DJ. Pooled analysis of prospective cohort studies of height, weight, and breast cancer risk. *Am J Epidemiol* 2000; 152: 514-527.
198. Jain MG, Ferrence RG, Rehm JT, Bondy SJ, Rohan TE, Ashley MJ, Cohen JE, Miller AB. Alcohol and breast cancer mortality in a cohort study. *Breast Cancer Research and Treatment* 2000; 64: 201-209.
199. Jain MG, Rohan TE, Howe GR, Miller AB. A cohort study of nutritional factors and endometrial cancer. *Eur J Epidemiol* 2000; 16: 899-905.
200. Smith-Warner SA, Spiegelman D, Yuan S-S.....Miller AB,.....Hunter DJ. Intake of fruits and vegetables and risk of breast cancer. A pooled analysis of cohort studies. *JAMA* 2001; 285: 769-776.
201. Smith-Warner, SA, Spiegelman D, Adami H-O,Miller AB,Hunter DJ. Types of dietary fat and breast cancer: a pooled analysis of cohort studies. *Int J Cancer* 2001, 92: 767-774.
202. Woolcott CG, Aronson KJ, Hanna WM, SenGupta S, McCready DR, Sterns EE, Miller AB. Organochlorines and breast cancer risk by receptor status, tumor size and grade (Canada). *Cancer Causes and Control* 2001; 12: 395-404.

203. Miller AB, Madalinska JB, Church T, Crawford D, Essink-Bot, ML, Goel V, de Koning HJ, Maatanem L, Pentikainen T. Review: Health-related quality of life and cost-effectiveness studies in the European randomised study of screening for prostate cancer and the U.S. Prostate, Lung, Colon and Ovary trial. *Eur J Cancer* 2001; 37: 2154-2160.
204. Collaborative Group on Hormonal Factors in Breast Cancer (A.B. Miller, member). Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58209 women with breast cancer and 101986 women without the disease. *Lancet* 2001; 358: 1389-1399.
205. Missmer SA, Smith-Warner SA, Spiegelman D, Yuan S_S, Admi HO, Beeson WL, van den Brandt PA, Fraser GE, Freudenheim JL, Godbloom RA, Graham S, Kushi LH, Miller AB, Potter JD, Rohan TE, Speizer FE, Toniolo P, Willett WC, Wolk A, Zeleniuch-Jacquette A, Hunter DJ. Meat and dairy food consumption and breast cancer: a pooled analysis of cohort studies. *Int J Epidemiol* 2002; 31: 78-85.
206. Terry P, Jain M, Miller AB, Howe GR, Rohan TE. Dietary intake of folic acid and colorectal cancer risk in a cohort of women. *Int J Cancer* 2002; 97: 864-867.
207. Terry PD, Miller AB, Rohan TE. Cigarette smoking and breast cancer risk: A long latency period? *Int J Cancer* 2002; 100: 723-728.
208. Terry PD, Miller AB, Rohan TE. Obesity and colorectal cancer risk in women. *Gut* 2002; 51: 191-194.
209. Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study-1: Breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. *Ann Intern Med* 2002; 137: 305-312.
210. Terry P, Jain M, Miller AB, Howe GR, Rohan TE. Dietary carotenoids and risk of breast cancer. *Am J Clin Nutr* 2002; 76: 883-888.
211. Collaborative Group on Hormonal Factors in Breast Cancer (A.B. Miller, member). Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries including 50302 women with breast cancer and 96973 women without the disease. *Lancet* 2002; 360: 187-195.
212. Smith-Warner, SA, Ritz J, Hunter DJ, Albanes D, Beeson L, Van den Brandt, Colditz G, Folsom AR, Fraser GE, Freudenheim JL, Giovannucci, E, Goldbloom A, Graham S, Kushi LE, Miller AB,Willett, WC. Dietary fat and risk of lung cancer in a pooled analysis of prospective studies. *Cancer Epidemiology, Biomarkers & Prevention* 2002; 11: 987-992.
213. Linseisen J, Wolfram G, Miller AB. Plasma 7b-hydroxycholesterol as a possible predictor of lung cancer risk. *Cancer Epidemiology, Biomarkers & Prevention* 2002; 11: 1630-1637.
214. Collaborative Group on Hormonal Factors in Breast Cancer (A.B. Miller, member). Alcohol, tobacco and breast cancer - collaborative reanalysis of individual data from 53

- epidemiological studies, including 58 515 women with breast cancer and 95 067 women without the disease. *British Journal of Cancer* 2002; 87: 1234-1245.
215. Agudo A, Slimani N, Ocke MC, Naska A, Miller AB, et al. Consumption of vegetables, fruit and other plant foods in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohorts from 10 European countries. *Public Health Nutrition* 2002; 5: 1179-1196.
 216. Haftenberger M, Lahmann PH, Panico S, Gonzalez CA, Seidell JC, Boeing H, Giurdanella MC, Krogh V, Bueno-de-Mesquita HB, Peeters PH, Skeie G, Hjartåker A, Rodriguez M, Quirós JR, Berglund G, Janlert U, Khaw KT, Spencer EA, Overvad K, Tjønneland A, Clavel-Chapelon F, Tehard B, Miller AB, Klipstein-Grobusch K, Benetou V, Kiriazis G, Riboli E, Slimani N. Overweight, obesity and fat distribution in 50- to 64-year old participants in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Public Health Nutrition* 2002; 5: 1147-1162.
 217. Linseisen J, Kesse E, Slimani N, Bueno-De-Mesquita HB, Ocké MC, Skeie G, Kumle M, Dorransoro Iraeta M, Morote Gómez P, Janzon L, Stattin P, Welch AA, Spencer EA, Overvad K, Tjønneland A, Clavel-Chapelon F, Miller AB, Klipstein-Grobusch K, Lagiou P, Kalapothaki V, Masala G, Giurdanella MC, Norat T, Riboli E. Consumption of added fats and oils in the European Prospective Investigation into Cancer and Nutrition (EPIC) centres across 10 European countries as assessed by 24-hour dietary recalls. *Public Health Nutrition* 2002; 5: 1227-1242.
 218. Linseisen J, Kesse E, Slimani N, Bueno-De-Mesquita HB, Ocké MC, Skeie G, Kumle M, Dorransoro Iraeta M, Morote Gómez P, Janzon L, Stattin P, Welch AA, Spencer EA, Overvad K, Tjønneland A, Clavel-Chapelon F, Miller AB, Klipstein-Grobusch K, Lagiou P, Kalapothaki V, Masala G, Giurdanella MC, Norat T, Riboli E. Meat consumption in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohorts: results from 24-hour dietary recalls. *Public Health Nutrition* 2002; 5: 1243-1258.
 219. Sieri S, Agudo A, Kesse E, Klipstein-Grobusch K, San-José B, Welch AA, Krogh V, Luben R, Allen N, Overvad K, Tjønneland A, Clavel-Chapelon F, Thiébaud A, Miller AB, Boeing H, Kolyva M, Saieva C, Celentano E, Ocké MC, Peeters PH, Brustad M, Kumle M, Dorransoro M, Fernandez Feito A, Mattisson I, Weinehall L, Riboli E, Slimani N. Patterns of alcohol consumption in 10 European countries participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) project. *Public Health Nutrition* 2002; 5: 1287-1296.
 220. Slimani N, Bingham S, Runswick S, Ferrari P, Day NE, Welch AA, Key TJ, Miller AB, Boeing H, Sleri S, Veglia F, Palli D, Panico S, Tomiso R, Bueno-de-Mesquita B, Ocke MC, Clavel-Chapelon F, Trichopoulou A, van Staveran WA, Riboli E. Group level validation of protein intakes estimated 24-hour diet recall and dietary questionnaires against 24-hour urinary nitrogen in the European Prospective Investigation into Cancer and Nutrition (EPIC) calibration study. *Cancer Epidemiology Biomarkers and Prevention* 2003; 12: 784-795.

221. Terry PD, Miller AB, Jones JG, Rohan TE. Cigarette smoking and the risk of invasive epithelial ovarian cancer in a prospective cohort study. *Eur J Cancer*, 2003; 39: 1157-64.
222. Jatoi I, Miller AB. Why is breast cancer mortality declining? *Lancet Oncology* 2003; 4: 251-254.
223. Smith-Warner SA, Spiegelman D, Yuan S-S, Albanes D, Beeson WL, van den Brandt PA, Feskanech D, Folsom AR, Fraser GE, Freudenheim JL, Giovannucci E, Goldbohm RA, Graham S, Kushi LH, Miller AB, Pietinen P, Rohan TE, Speizer FE, Willett WC, Hunter DJ. Fruits, vegetables and lung cancer: a pooled analysis of cohort studies. *Int J Cancer* 2003; 107: 1001-1011.
224. Miller AB, Altenburg H-P, Bueno de Mesquita, B, Boshuizen HC, Agudo A, Berrino F, Gram IT, Janson L, Linseisen J, Overvad K, Rasmuson T, Vineis P, Lukanova A, Allen N, Amiano P, Barricarte A, Berglund G, Boeing H, Clavel-Chapelon F, Day NE, Hallmans G, Lund E, Martinez C, Navarro C, Palli D, Panico S, Peeters PH, Quiros JR, Tjonneland A, Tumino R, Trichopoulou A, Trichopoulos D, Slimani N, Riboli E. Fruits and vegetables and lung cancer: Findings from the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer* 2004; 108: 269-276.
225. Key TJ, Allen N, Appleby P, Overvad K, Tjonneland A, Miller A, Boeing H, Karalis D, Psaltopoulou T, Berrino F, Palli D, Panico S, Tumino R, Vineis P, Bueno-de-Mesquita, HB, Kiemeny L, Peeters PHM, Martinez C, Dorronsoro M, Gonzalez C, Chirlaque MD, Quiros JR, Ardanaz E, Berglund G, Egevad L, Hallmans G, Stattin P, Bingham S, Day N, Gann P, Kaaks R, Ferrari P, Riboli E. Fruits and vegetables and Prostate cancer: no association among 1,104 cases in a prospective study of 130,544 men in the European Prospective Investigation into Cancer and nutrition (EPIC). *Int J Cancer* 2004; 109: 119-124.
226. Rijnsburger AI, van Oortmarssen GJ, Boer R, Draisma G, To T, Miller AB, de Koning HJ. Mammography benefit in the Canadian National Breast Screening Study-2: a model evaluation. *Int J Cancer* 2004; 110: 756-762.
227. Mannisto S, Smith-Warner SA, Spiegelman D, Albanes D, Anderson K, van den Brandt P, Cerhan JR, Colditz G, Feskanich D, Freudenheim JL, Giovannucci E, Goldbohm RA, Graham S, Miller AB, Rohan TE, Virtamo J, Willett WC, Hunter DJ. Dietary Carotenoids and risk of lung cancer in a pooled analysis of seven cohort studies. *Cancer Epidemiology, Biomarkers & Prevention* 2004; 13: 40-48.
228. Eunyoung Cho E, Smith-Warner SA, Spiegelman D, Beeson, WL, van den Brandt PA, Colditz GA, Folsom, AR, Fraser GE, Freudenheim JL, Giovannucci E, Goldbohm RA, Graham S, Miller AB, Pietinen P, Potter JD, Rohan TE, Terry P, Toniolo P, Virtanen MJ, Willett WC, Wolk A, Wu K, Yaun S-S, Zeleniuch-Jacquotte A, Hunter DJ. Dairy Foods, Calcium, and Colorectal Cancer: A Pooled Analysis of 10 Cohort Studies. *J Natl Cancer Inst* 2004; 96: 1015-1022.

229. Collaborative Group on Hormonal Factors in Breast Cancer (A.B. Miller, member). Breast cancer and abortion: collaborative reanalysis of individual data from 53 epidemiological studies, including 83000 women with breast cancer from 16 countries. *Lancet* 2004; 363: 1007-1016.
230. Silvera, SAN, Rohan, TE, Jain M, Terry PD, Howe GR, Miller AB. Glycemic index, glycemic load, and pancreatic cancer risk (Canada). *Cancer Causes Control*, 2005; 16: 431-436.
231. Shen Y, Yang Y, Inoue LYT, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: Analysis of randomised screening trials. *J Natl Cancer Inst* 2005; 97: 1195-1203.
232. Zhang B, Ferrence R, Cohen J, Bondy S, Ashley MJ, Rehm J, Jain M, Rohan T, Miller A. Smoking cessation and lung cancer mortality in a cohort of middle-aged Canadian women. *Annals of Epidemiology* 2005; 15: 302-309.
233. Onland-Moret NC, Peeters PHM, van Gils CH, Clavel-Chapelon F, Key T, Tjønneland A, Trichopoulou A, Kaaks R, Manjer J, Panico S, Palli D, Tehard B, Stoikidou M, Bueno-De-Mesquia HB, Boeing H, Overvad K, Lenner P, Quiro JR, Chirfiauque MD, Miller AB, Khaw KT, Riboli E. Age at menarche in relation to adult height. The EPIC study. *Am J Epidemiol* 2005; 161: 1-10.
234. Silvera SAN, Miller AB, Rohan, TE. Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: a prospective cohort study. *Cancer Causes Control*, 2005; 16: 1059-1063.
235. Boulos S, Gadallah M, Neguib S, Essam Ea, Youssef A, Costa A, Mitra I, Miller AB. Breast screening in the emerging world: High prevalence of breast cancer in Cairo. *The Breast* 2005; 14: 340-346.
236. Cong XY, Shen Y, Miller AB. Estimation of age-specific sensitivity and sojourn time in breast cancer screening studies. *Statistics in Medicine* 2005; 3123-3138
237. Silvera SAN, Miller AB, Rohan, TE. Risk factors for thyroid cancer: A prospective cohort study. *Int J Cancer* 2005; 116: 433-438.
238. Rehm J, Zhang B, Bondy S, Ashley MJ, Cohen J, Ferrence R, Jain M, Miller A, Rohan T. The effect of smoking on the relationship between alcohol consumption and all-cause mortality in Canadian women. *Contemporary Drug Problems*, 2005; 32: 373-386.
239. Jain MG, Miller AB, Rohan TE, Rehm JT, Bondy SJ, Ashley MJ, Cohen JE, Ferrence RG. Body mass index and mortality in women: Follow-up of the Canadian National Breast Screening Study cohort. *International Journal of Obesity* 2005; 29: 792-797.
240. Silvera SA, Jain M, Howe GR, Miller AB, Rohan TE. Energy balance and breast cancer risk: a prospective cohort study. *Breast Cancer Res. Treat.* 2006; 97: 97-106.

241. Cho E, Hunter DJ, Spiegelman D, Albanes D, Beeson WL, van den Brandt PA, Colditz GA, Feskanich D, Folsom AR, Fraser GE, Freudenheim JL, Giovannucci E, Goldbohm RA, Graham S, Miller AB, Rohan TE, Sellers TA, Virtamo J, Willett WC, Smith-Warner SA. Intakes of vitamins A,C and E and folate and multivitamins and lung cancer. A pooled analysis of 8 prospective studies. *Int J Cancer* 2006; 118: 970-978.
242. Hanin LG, Miller A, Zorin AV, Yakovlev AY. Chapter 10: The University of Rochester Model of Breast Cancer Detection and Survival. *J Natl Cancer Inst Monogr* 2006; 36: 66-78.
243. Koushik A, Hunter DJ, Spiegelman D, Anderson KE, Buring JE, Freudenheim JL, Goldbohm RA, Hankinson SE, Larsson SC, Leitzmann M, Marshall JR, McCullough ML, Miller AB, Rodriguez C, Rohan TE, Ross JA, Schatzkin A, Schouten LJ, Willett WC, Wolk A, Zhang SM, Smith-Warner SA. Intake of the major carotenoids and the risk of epithelial ovarian cancer in a pooled analysis of 10 cohort studies. *Int J Cancer* 2006; 119: 2148-2154.
244. Genkinger, J.M., Hunter, D.J., Spiegelman, D., Anderson, K.E., Arslan, A., Beeson, W.L., Buring, J.E., Fraser, G.E., Freudenheim, J.L., Goldbohm, R.A., Hankinson, S.E., Jacobs Jr., D.R., Koushik, A., Lacey Jr., J.V., Larsson, S.C., Leitzmann, M., McCullough, M.L., Miller, A.B., Rodriguez, C., Rohan, T.E., Scheuten, L.J., Shore, R., Smit, E., Wolk, A., Zhang, S.M., Smith-Warner, S.A. Dairy products and ovarian cancer: A pooled analysis of 12 cohort studies. *Cancer Epidemiology Biomarkers and Prevention* 2006; 15: 364-372
245. Genkinger JM, Hunter DJ, Spiegelman D, Anderson KE, Beeson WL, Buring JE, Colditz GA, Fraser GE, Freudenheim JL, Goldbohm RA, Hankinson SE, Koenig KL, Larsson SC, Leitzmann M, McCullough ML, Miller AB, Rodriguez C, Rohan TE, Ross JA, Schatzkin A, Schouten LJ, Smit E, Willett WC, Wolk A, Zeleniuch-Jacquotte A, Zhang SM, Smith-Warner SA. A pooled analysis of 12 cohort studies of dietary fat, cholesterol and egg intake and ovarian cancer. *Cancer Causes Control.* 2006; 17(3): 273-285.
246. Genkinger JM, Hunter DJ, Spiegelman D, Anderson KE, Buring JE, Freudenheim JL, Goldbohm RA, Harnack L, Hankinson SE, Larsson SC, Leitzmann M, McCullough ML, Marshall J, Miller AB, Rodriguez C, Rohan TE, Schatzkin A, Schouten LJ, Wolk A, Zhang SM, Smith-Warner SA. Alcohol intake and ovarian cancer risk: a pooled analysis of 10 cohort studies. *Br J Cancer* 2006; 94: 757-762.
247. Smith-Warner SA, Spiegelman D, Ritz J, Albanes D, Beeson WL, Bernstein L, Berrino F, van den Brandt PA, Buring JE, Cho E, Colditz GA, Folsom AR, Freudenheim JL, Giovannucci E, Goldbohm RA, Graham S, Harnack L, Horn-Ross PL, Krogh V, Leitzmann MF, McCullough ML, Miller AB, Rodriguez C, Rohan TE, Schatzkin A, Shore R, Virtanen M, Willett WC, Wolk A, Zeleniuch-Jacquotte A, Zhang SM, Hunter DJ. Methods for Pooling Results of Epidemiologic Studies. *The Pooling Project of Prospective Studies of Diet and Cancer. Am J Epidemiol* 2006; 163: 1053-1064.

248. Cui Y, Miller AB, Rohan TE. Cigarette smoking and breast cancer risk: update of a prospective cohort study. *Breast Cancer Res. Treat.* 2006; 100: 293-299.
249. Silvera SAN, Jain M, Howe GR, Miller AB, Rohan TE. Glycemic index, glycemic load, and ovarian cancer risk: a prospective cohort study. *Pub Hlth Nutr* 2007; 10:1076-1081.
250. Silvera SAN, Jain M, Howe GR, Miller AB, Rohan TE. Dietary fiber intake and ovarian cancer risk: a prospective cohort study. *Cancer Causes Control* 2007; 18: 335-341.
251. Pinsky PF, Miller A, Kramer BS, Church T, Reding D, Prorok P, Gelman E, Schoen RE, Buys S, Hayes RB, Berg CD. Evidence of a healthy volunteer effect in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *Am J Epidemiol* 2007; 165: 874-878.
252. Kabat, G.C., Miller, A.B., Jain, M., Rohan, T.E.. Dietary iron and heme iron intake and risk of breast cancer: a prospective cohort study. *Cancer Epidemiol Biomarkers Prev* 2007; 16: 1306-1308.
253. Kabat GC, Miller AB, Rohan T. Reproductive and hormonal risk factors and risk of lung cancer in women: A prospective cohort study. *Int J Cancer* 2007; 120: 2214-2220.
254. Linseisen J, Rohrmann S, Miller AB, Bueno de Mesquita, B, Buchner FL, Agudo A, Vineis P, Gram IT, Janson L, Krogh V, Overvad K, Rasmuson T, Schulz M, Pischon T, Kaaks R, Neiters A, Allen NE, Key TJ, Bingham S, Khaw K-T, Amiano P, Barricarte A, Martinez C, Navarro C, Quiros R, Clavel-Chapelon F, Boutron-Ruault M-C, Touvier M, Peeters PH, Berglund G, Hallmans G, Lund E, Palli D, Panico S, Tumino R, Tjonneland A, Olsen A, Trichopoulou A, Trichopoulos D, Autier P, Boffetta, P, Slimani N, Riboli E. Fruits and vegetable consumption and lung cancer risk: Updated information from the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer* 2007; 121: 1103-1114.
255. Lee JL, Hunter DJ, Spiegelman D, Adamai HO, Albanes D, Bernstein L, van den Brandt PA, Buring JE, Cho E, Folsom AR, Freudenheim JL, Giovannucci E, Horn-Ross PL, Leitzmann MF, McCullough ML, Miller AB, Parker AS, Rodriguez C, Rohan TE, Schatzkin A, Schouten LJ, Virtanen M, Willett WC, Wolk A, Zhang SM, Smith-Warner SA. Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. *J Natl Cancer Inst* 2007; 99: 801-810.
256. Lee JL, Hunter DJ, Spiegelman D, Adamai HO, Bernstein L, van den Brandt PA, Buring JE, Cho E, English D, Folsom AR, Freudenheim JL, Giles G G, Giovannucci E, Horn-Ross PL, Leitzmann MF, Marshall JR, McCullough ML, Miller AB, Parker AS, Pietinen P, Rodriguez C, Rohan TE, Schatzkin A, Schouten LJ, Willett WC, Wolk A, Zhang SM, Smith-Warner SA. Intakes of coffee, tea, milk, soda and juices and renal cell cancer in a pooled analysis of 13 prospective studies. *Int J Cancer* 2007; 121: 2246-2253.

257. Koushik A, Hunter DJ, Spiegelman D, Beeson WL, van den Brandt PA, Buring JE, Calle EE, Chu E, Fraser GE, Freudenheim JL, Fuchs CS, Giovannucci E, Goldbohm A, Harnack L, Jacobs DR, Kato I, Krogh V, Larsson SC, Leitzmann MF, Marshall JR, McCullough ML, Miller AB, Pietinen P, Rohan TE, Schatzkin A, Sieri S, Virtanen M, Wolk A, Zeleniuch-Jaquotte A, Zhang SM, Smith-Warner SA. Fruits, vegetables and colon cancer risk in a pooled analysis of 14 cohort studies. *J Natl Cancer Inst* 2007; 99: 1471-1483.
258. Hakama M, Auvinen A, Day NE, Miller AB. Sensitivity in cancer screening. *J Med Screen* 2007; 14: 74-77.
259. Kabat GC, Miller AB, Rohan TE. Oral contraceptive use, hormone replacement therapy, reproductive history and risk of colorectal cancer in women. *Int J Cancer* 2008; 122: 643-646.
260. Schouten LJ, Rivera C, Hunter DJ, Spiegelman D, Adami HO, Arslan A, Beeson WL, van den Brandt PA, Buring JE, Folsom AR, Fraser GE, Freudenheim JL, Goldbohm RA, Hankinson SE, Lacey JV, Leitzmann M, Lukanova A, Marshall JR, Miller AB, Patel AV, Rodriguez C, Rohan TE, Ross JA, Wolk A, Zhang SM, Smith-Warner SA. Height, Body Mass Index, and Ovarian Cancer: A Pooled Analysis of 12 Cohort Studies. *Cancer Epidemiol Biomarkers Prev* 2008; 17: 902–912.
261. Grubb RL, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP, Riley TL, Mabie JE, Levin DL, Chia D, Kramer BS, Reding DJ, Church TR, Yokochi LA, Kvale PA, Weissfeld JL, Urban DA, Buys SS, Gelmann EP, Ragard LR, Crawford ED, Prorok PC, Gohagan JK, Berg CD, Andriole GL, for the PLCO Project Team. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. *BJU International*, 2008; 102: 1524–1530.
262. Lee JE, Spiegelman D, Hunter DJ, Albanes D, Bernstein L, van den Brandt PA, Buring JE, Cho E, English DR, Freudenheim JL, Giles GG, Graham S, Horn-Ross PL, Håkansson N, Leitzman MF, Männistö S, McCullough ML, Miller AB, Parker AS, Rohan TE, Schatzkin A, Schouten LJ, Sweeney C, Willett WC, Wolk A, Zhang SM, Smith-Warner SA. Fat, Protein, and Meat Consumption and Renal Cell Cancer Risk: A Pooled Analysis of 13 Prospective Studies. *J Natl Cancer Inst* 2008; 100: 1695-1706.
263. Andriole GL, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, Crawford ED, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD for the PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. *New Eng J Med* 2009; 360: 1310-19.
264. Howlett RI, Miller AB, Pasut G, Mai V. Defining a strategy to evaluate cervical cancer prevention and early detection in the era of HPV vaccination. *Prev. Med* 2009; 48: 432-437.

265. Duell EJ, Maisonneuve P, Baghurst PA, Bueno-de-Mesquita HB, Ghadirian P, Miller AB, Zatonski W, Vrieling A, Boffetta P, Boyle P.
Menstrual and reproductive factors and pancreatic cancer in the SEARCH program of the IARC. *Cancer Causes Control*. 2009; 20(9):1757-1762.
266. Ott JJ, Ullrich A, Miller AB. The importance of early symptom recognition in the context of early detection and cancer survival. *Eur. J. Cancer* 2009; 45: 2743-2748.
267. Sue LY, Schairer C, Ma X, Williams C, Chang S-C, Miller AB, McCarty CA, Willcox BJ, Ziegler RG. Energy Intake and Risk of Postmenopausal Breast Cancer: An Expanded Analysis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort. *Cancer Epidemiol Biomarkers Prev*. 2009; 18(11): 2842–2850.
268. Maisonneuve P, Lowenfels AB, Bueno-de-Mesquita HB, Ghadirian P, Baghurst PA, Zatonski WA, Miller AB, Duell EJ, Boffetta P, Boyle P.
Past medical history and pancreatic cancer risk: Results from a multicenter case-control study. *Ann Epidemiol*. 2010; 20(2): 92-98.
269. Miller AB, Green LM. Electric and Magnetic fields at power frequencies. *Chronic Diseases in Canada* 2010; 29 Suppl1: 69-83.
270. Mitra I, Mishra GA, Singh S, Aranke S, Notani P, Badwe R, Miller AB, Daniel EE, Gupta S, Uplap P, Thakur MH, Ramani S, Kerkar R, Ganesh B, Shastri SS. A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. *Int. J. Cancer* 2010; 126: 976–984.
271. Zhang X, Albanes D, Beeson WL, van den Brandt PA, Buring JE, Flood A, Freudenheim JL, Giovannucci EL, Goldbohm RA, Jaceldo-Siegl K, Jacobs EJ, Krogh V, Larsson SC, Marshall JR, McCullough ML, Miller AB, Robien K, Rohan TE, Schatzkin A, Sieri S, Spiegelman D, Virtamo J, Wolk A, Willett WC, Zhang SM, Smith-Warner SA. Risk of Colon Cancer and Coffee, Tea, and Sugar-Sweetened Soft Drink Intake: Pooled Analysis of Prospective Cohort Studies. *J Natl Cancer Inst* 2010; 102: 1–13.
272. Doria-Rose VP, Marcus PM, Miller AB, Bergstralh EJ, Mandel JS, Tockman MS, Prorok PC. Does the source of death information affect cancer screening efficacy results? A study of the use of mortality review versus death certificates in four randomized trials. *Clin Trials*. 2010; 7: 69-77.
273. Pinsky PF, Black A, Kramer BS, Miller A, Prorok PC, Berg C. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. *Clin Trials* 2010; 7: 303-311.
274. Johnson KC, Miller AB, Collishaw NE, Palmer JR, Hammond SK, Salmon AG, Cantor KP, Miller MD, Boyd NF, Millar J, Turcotte F. Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk (2009). *Tobacco Control* 2011; 20:e.doi:10.1136/tc.

275. Bertuccio P, La Vecchia C, Silverman DT, Petersen GM, Bracci PM, Negri E, Li D, Risch HA, Olson SH, Gallinger S, Miller AB, Bueno-de-Mesquita HB, Talamini R, Polesel J, Ghadirian P, Baghurst PA, Zatonski W, Fontham ET, Bamlet WR, Holly EA, Lucenteforte E, Hassan M, Yu H, Kurtz RC, Cotterchio M, Su J, Maisonneuve P, Duell EJ, Bosetti C, Boffetta P. Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). *Annals of Oncology* Advance Access published January 18, 2011. doi:10.1093/annonc/mdq613
276. Soskolne CL, Jhangri GS, Scott HM, Brenner DR, Siemiatycki J, Lakhani R, Gérin M, Dewar R, Miller AB, Risch HA. A Population-Based Case-Control Study of Occupational Exposure to Acids and the Risk of Lung Cancer: Evidence for Specificity of Association. *Int J Occup Environ Health* 2011; 17: 1–8
277. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlan G, Kramer BS, Miller AB, Xu J-L, Prorok PC, Gohagan JK, Berg CD, for the PLCO Project Team. Effect of Screening on Ovarian Cancer Mortality. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. *JAMA* 2011; 305: 2295-303.
278. Marcus PM, Gareen IF, Miller AB, Rosenbaum J, Keating K, Aberle DR, Berg CD. The National Lung Screening Trial's Endpoint Verification Process: Determining the cause of death. *Contemp Clin Trials* 2011; doi:10.1016/j.cct.2011.07.003
279. Miller AB, Baines CJ. The role of clinical breast examination and breast self-examination. *Prev. Med.* 2011; 53: 118-120. doi:10.1016/j.ypmed.2011.05.001
280. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlan G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC, for the PLCO Project Team. Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up. *J Natl Cancer Inst* 2012;104:125–32.
281. Lucenteforte E, La Vecchia C, Silverman D, Petersen GM, Bracci PM, Ji BT, Bosetti C, Li D, Gallinger S, Miller AB, Bueno-de-Mesquita HB, Talamini R, Polesel J, Ghadirian P, Baghurst PA, Zatonski W, Fontham E, Bamlet WR, Holly EA, Gao YT, Negri E, Hassan M, Cotterchio M, Su J, Maisonneuve P, Boffetta P, Duell EJ. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case–Control Consortium (PanC4). *Annals of Oncology* 2012; 23: 374–382.
282. Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, Crawford ED, Fouad MN, Isaacs C, Reding DJ, Weissfeld JL, MD, Yokochi LA, O'Brien B, Ragard

- LR, Rathmell JM, Riley TL, Wright P, Caparaso N, Hu P, Izmirlian G, Pinsky PF, Prorok PC, Kramer BS, Miller AB, Gohagan, JK, Berg CD, for the PLCO Project Team. Screening by Chest Radiograph and Lung Cancer Mortality. The Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Trial. *JAMA*. 2011; 306(17):doi: 10.1001/jama. 1591.
283. Genkinger JM, Li R, Spiegelman D, Anderson KE, Albanes D, Bergkvist L, Bernstein L, Black A, van den Brandt PA, English DR, Freudenheim JL, Fuchs CS, Giles G, Giovannucci E, Goldbohm RA, Horn-Ross PL, Jacobs EJ, Koushik A, Mannisto S, Marshall JR, Miller AB, Patel AV, Robien K, Rohan TE, Schairer C, Stolzenberg-Solomon R, Wolk A, Ziegler RG, Smith-Warner SA. Coffee, Tea, and Sugar-Sweetened Carbonated Soft Drink Intake and Pancreatic Cancer Risk: A Pooled Analysis of 14 Cohort Studies. *Cancer Epidemiology, Biomarkers and Prevention* 2011; 21(2); 305–18.
284. Collaborative Group on Epidemiological Studies of Ovarian Cancer (Miller AB, member) Ovarian Cancer and Body Size: Individual Participant Meta-Analysis Including 25,157 Women with Ovarian Cancer from 47 Epidemiological Studies. *PLoS Med* 2012; 9(4): e1001200. doi:10.1371/journal.pmed.1001200
285. Taghipour S, Banjevic D, Fernandes J, Miller AB, Montgomery N, Harvey BJ, Jardine AKS. Incidence of invasive breast cancer in the presence of competing mortality: the Canadian National Breast Screening Study. *Breast Cancer Res Treat* 2012; 134: 839-851. DOI 10.1007/s10549-012-2113-6
286. Taylor KL, Luta G, Miller AB, Church TR, Kelly SP, Muenz LR, Davis KM, Dawson DL, Edmond S, Reding D, Mabie JE, Riley TL. Long-Term Disease-Specific Functioning Among Prostate Cancer Survivors and Noncancer Controls in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *J Clin Oncol* 2012; 10.1200/JCO.2011.41.2767.
287. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED, Fouad MN, Isaacs C, Johnson CC, Reding DJ, O'Brien B, Carrick DM, Wright P, Riley TL, Purdue MP, Izmirlian G, Kramer BS, Miller AB, Gohagan JK, Prorok PC, Berg CD, for the PLCO Project Team. Colorectal-Cancer Incidence and Mortality with Screening Flexible Sigmoidoscopy. *New Engl J Med* 2012;(366)25:2345-57.
288. Collaborative Group on Epidemiological Studies of Ovarian Cancer (Miller AB, member). Ovarian cancer and smoking: individual participant meta-analysis including 28 114 women with ovarian cancer from 51 epidemiological studies. *Lancet Oncology* 2012; 13(9): 946-956.
289. Koushik A, Spiegelman D, Albanes D, Anderson KE, Bernstein B, van den Brandt PA, Bergkvist L, English DR, Freudenheim JL, Fuchs CS, Genkinger JM, Giles GG, Goldbohm RA, Horn-Ross PL, Männistö S, McCullough ML, Millen AE, Miller AB, Robien K, Rohan TE, Schatzkin† A, Shikany JM, Stolzenberg-Solomon RZ, Willett

- WC, Wolk A, Ziegler RG, Smith-Warner SA. Intake of Fruits and Vegetables and Risk of Pancreatic Cancer in a Pooled Analysis of 14 Cohort Studies. *Am J Epidemiol*. 2012;176(5): 373–386.
290. Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT, Negri E, Li D, Risch HA, Olson SH, Gallinger S, Miller AB, Bueno-de-Mesquita HB, Talamini R, Polesel J, Ghadirian P, Baghurst PA, Zatonski W, Fontham E, Bamlet WR, Holly EA, Bertuccio P, Gao YT, Hassan M, H. Yu H, Kurtz RC, Cotterchio M, Su J, Maisonneuve P, Duell EJ, Boffetta P, La Vecchia C. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). *Annals of Oncology* 2012; 23: 1880–1888.
 291. Dickinson JA, Stankiewicz A, Popadiuk C, Pogany L, Onysko J, Miller AB. Reduced cervical cancer incidence and mortality in Canada: national data from 1932 to 2006. *BMC Public Health* 2012; 12: 992 doi:10.1186/1471-2458-12-992
 292. Popadiuk C, Stankiewicz A, Dickinson J, Pogany L, Miller AB, Onysko J. Invasive Cervical Cancer Incidence and Mortality Among Canadian Women Aged 15 to 29 and the Impact of Screening. *J Obstet Gynaecol Can* 2012; 34(12): 1167–1176.
 293. Taghipour S, Banjevic D, Fernandes J, Miller AB, Montgomery N, Jardine KSA, Harvey B. Predictors of competing mortality to invasive breast cancer incidence in the Canadian National Breast Screening study. *BMC Cancer* 2012; 12:299. DOI: 10.1186/1471-2407-12-29
 294. Miller AB. Commentary: The future of cancer prevention. *Preventive Medicine* 2012; 55: 554-555.
 295. Collaborative Group on Hormonal Factors in Breast Cancer (Miller AB, member). Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. *Lancet Oncol* 2012; 13: 1141–1151.
 296. Barisic A, Taghipour S, Banjevic D, Miller AB, Montgomery N, Jardine A, Harvey BJ. Commentary: Optimizing Canadian Breast Cancer Screening Strategies: A Perspective for Action. *Can J Public Health* 2012; 103(6): 417-419.
 297. Kabat, GC, Heo M, Miller AB, Rohan TE. Scaling of Weight for Height in Relation to Risk of Cancer at Different Sites in a Cohort of Canadian Women. *Am J Epidemiol*. 2013; 177(1): 93–101.
 298. Taghipour S, Banjevic D, Miller AB, Montgomery N, Jardine AKS, Harvey BJ. Parameter estimates for invasive breast cancer progression in the Canadian National Breast Screening Study. *Br J Cancer* 2013; 108: 542–548.
 299. Jung S, Spiegelman D, Baglietto L, Bernstein L, Boggs DA, van den Brandt PA, Buring JE, Cerhan JR, Gaudet MM, Giles GG, Goodman G, Hakansson N, Hankinson SE, Helzlsouer K, Horn-Ross PL, Inoue M, Krogh V, Lof M, McCullough ML, Miller AB, Neuhauser ML, Palmer JR, Park Y, Robien K, Rohan TE, Scarmo S, Schairer C,

- Schouten LJ, Shikany JM, Sieri S, Tsugane S, Visvanathan K, Weiderpass E, Willett WC, Wolk A, Zeleniuch-Jacquotte A, Zhang SM, Zhang X, Ziegler RG, Smith-Warner SA. Fruit and Vegetable Intake and Risk of Breast Cancer by Hormone Receptor Status. *J Natl Cancer Inst.* 2013; 105:219-236. PMID: 2334925
300. Evans WK, Wolfson MC, Flanagan WM, Shin J, Goffin J, Miller AB, Asakawa K, Earle C, Mittmann N, Fairclough L, Oderkirk J, Finès P, Gribble S, Hoch J, Hicks C, Omariba DW, Ng E. Canadian Cancer Risk Management Model: evaluation of cancer control. *Int J Technol Assess Health Care.* 2013 ; 29(2): 131-139.
 301. Kabat GC, Heo M, [Kamensky V](#), [Miller AB](#), [Rohan TE](#). Adult height in relation to risk of cancer in a cohort of Canadian women. *Int J Cancer* 2013; 132(5): 1125-32.
 302. Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang Y-B, Wolk A, Wentzensen N, Weiss NS, Webb PM, van den Brandt PA, van de Vijver K, Thompson PJ, The Australian National Endometrial Cancer Study Group, Strom BL, Spurdle AB, Soslow RA, Shu X, Schairer C, Sacerdote C, Rohan TE, Robien K, Risch HA, Ricceri F, Rebbeck TR, Rastogi R, Prescott J, Polidoro S, Park Y, Olson SH, Moysich KB, Miller AB, McCullough ML, Matsuno RK, Magliocco AM, Lurie G, Lu L, Lissowska J, Liang X, Lacey Jr JV, Kolonel LN, Henderson BE, Hankinson SE, Håkansson N, Goodman MT, Gaudet MM, Garcia-Closas M, Friedenreich CM, Freudenheim JL, Doherty J, De Vivo I, Courneya KS, Cook LS, Chen C, Cerhan JR, Cai H, Brinton LA, Bernstein L, Anderson KE, Anton-Culver H, Schouten LJ, Horn-Ross PL. Type I and II Endometrial Cancers: Have They Different Risk Factors? *J Clin Oncol* 2013; 10.1200/JCO.2012.48.2596 <http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.48.2596>
 303. Davis DL, Kesari S, Soskolne CL, Miller AB, Stein Y. Swedish review strengthens grounds for concluding that radiation from cellular and cordless phones is a probable human carcinogen. *Pathophysiology* 2013; 20: 123–129.
 304. Dickinson JA, Miller AB, Popadiuk C. When to start cervical screening: epidemiological evidence from Canada. *BJOG* 2013; DOI: 10.1111/1471-0528.12484.
 305. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. *BMJ* 2014.348:g366 doi: 10.1136/bmj.g366.
 306. Catsburg C, Miller AB, Rohan TE. Adherence to cancer prevention guidelines and risk of breast cancer. *Int J Cancer* 2014; 135: 2444–2452.
 307. Genkinger JM, Wang M, Li R, Albanes D, Anderson KE, Bernstein L, van den Brandt PA, English DR, Freudenheim JL, Fuchs CS, Gapstur S M, Giles GG, Goldbohm RA, Håkansson N, Horn-Ross PL, Koushik A, Marshall JR, McCullough ML, Miller AB, Robien K, Rohan TE, Schairer C, Silverman DT, Stolzenberg-Solomon RZ, Virtamo J, Willett WC, Wolk A, Ziegler RG, Smith-Warner SA. Dairy products and pancreatic cancer risk: a pooled analysis of 14 cohort studies. *Ann Oncol* 2014; 25: 1106-1115.
 308. Davis KM, Kelly SP, Luta G, Tomko C, Miller AB, Taylor KL. The Association of

Long-term Treatment-related Side Effects with Cancer-specific and General Quality of Life among Prostate Cancer Survivors. *Urology* 2014; 84: 300e306.

309. To T, Wall C, Baines CJ, Miller AB. Is carcinoma in situ a precursor lesion of invasive breast cancer? *Int. J. Cancer* 2014; 135: 1646–1652.
310. Bosetti C, Rosato V, Li D, Silverman D, Petersen GM, Bracci PM, Neale RE, Muscat J, Anderson K, Gallinger S, Olson SH, Miller AB, Bas Bueno-de-Mesquita H, Scelo G, Janout V, Holcatova I, Lagiou P, Serraino D, Lucenteforte E, Fabianova E, Ghadirian P, Baghurst PA, Zatonski W, Foretova L, Fontham E, Bamlet WR, Holly EA, Negri E, Hassan M, Prizment A, Cotterchio M, Cleary S, Kurtz RC, Maisonneuve P, Trichopoulos D, Polesel J, Duell EJ, Boffetta P, La Vecchia C. Diabetes, antidiabetic medications and pancreatic cancer risk: an analysis from the international pancreatic cancer case-control consortium. *Annals of Oncology* 2014; 25: 2065-2072. doi: 10.1093/annonc/mdu276
311. Narod SA, Sun P, Wall C, C. Baines C, Miller AB. Impact of Screening mammography on mortality from breast cancer before age 60 in women 40-49 years of age. *Current Oncology* 2014; 21: 217-221.
312. Collaborative Group on Epidemiological Studies of Ovarian Cancer (Miller AB, member). Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. *Lancet* 2015; 385 (9980): 1835-1842.
313. Marcus PM, Prorok PC, Miller AB, DeVoto EJ, Kramer BS. Conceptualizing Overdiagnosis in Cancer Screening. *J Natl Cancer Inst.* 2015; 107 (1): djv014
doi: 10.1093/jnci/djv014
314. Catsburg C, Miller AB, Rohan TE. Active cigarette smoking and risk of breast cancer. *Int J Cancer* 2015; 136 (9): 2204–2209.
315. Morgan LL, Miller AB, Sasco A, Davis DL. Mobile phone radiation causes brain tumors and should be classified as a probable human carcinogen (2A) (Review). *Int J Oncology* 2015; 46(5):1865-1871. DOI: 10.3892/ijo.2015.2908
316. To T, Zhu J, Villeneuve PJ, Simatovic J, Feldman L, Gao C, Williams D, Chen H, Weichenthal S, Wall C, Miller AB. Chronic disease prevalence in women and air pollution – A 30-year longitudinal cohort study. *Environment International* 2015; 80: 26-32. doi:10.1016/j.envint.2015.03.017
317. Choi BCK, Wigle DT, Johansen H, Losos J, Fair ME, Napke E, Anderson LJ, Davies JW, White K, Miller AB, Li FCK, Stachenko S, Lindsay J, Gaudette LA, Nair C, Levy I, Morrison H, Silins J, Bouchard F, Tonmyr L, Villeneuve PJ, McRae L, Johnson KC, Lane RSD, Probert A. Retracing the history of the early development of national chronic disease surveillance in Canada and the major role of the Laboratory Centre for Disease Control (LCDC) from 1972 to 2000. *Health Promotion and Chronic Disease Prevention in Canada* 2015; 35: 34-43.

318. Pearce NE, Blair A, Vineis P, Ahrens W, Andersen A, Anto JM, Armstrong BK, Baccarelli AA, Beland FA, Berrington A, Bertazzi PA, Birnbaum LS, Brownson RC, Bucher JR, Cantor KP, Cardis E, Cherrie JW, Christiani DC, Cocco P, Coggon D, Comba P, Demers PA, Dement JM, Douwes J, Eisen EA, Engel LS, Fenske RA, Fleming LE, Fletcher T, Fontham E, Forastiere F, Frentzel-Beyme R, Fritschi L, Gerin M, Goldberg M, Grandjean P, Grimsrud TK, Gustavsson P, Haines A, Hartge P, Hansen J, Hauptmann M, Heederik D, Hemminki K, Hemon D, Hertz-Picciotto I, Hoppin JA, Huff J, Jarvholm B, Kang D, Karagas MR, Kjaerheim K, Kjuus H, Kogevinas M, Kriebel D, Kristensen P, Kromhout H, Laden F, LeBailly P, LeMasters G, Lubin JH, Lynch C, Lynge E, 't Mannetje A, McMichael AJ, McLaughlin JR, Marrett L, Martuzzi M, Merchant JA, Merler E, Merletti F, Miller A, Mirer FE, Monson R, Nordby KC, Olshan AF, Parent ME, Perera FP, Perry MJ, Pesatori AC, Pirastu R, Porta M, Pukkala E, Rice C, Richardson DB, Ritter L, Ritz B, Ronckers CM, Rushton L, Rusiecki JA, Rusyn I, Samet JM, Sandler DP, de Sanjose S, Schernhammer E, Seniori Costantini A, Seixas N, Shy C, Siemiatycki J, Silvermann DT, Simonato L, Smith AH, Smith MT, Spinelli JJ, Spitz MR, Stallones L, Stayner LT, Steenland K, Stenzel M, Stewart BW, Stewart PA, Symanski E, Terracini B, Tolbert PE, Vainio H, Vena J, Vermeulen R, Victora CG, Ward EM, Weinberg CR, Weisenburger D, Wesseling C, Weiderpass E, Zahm SH. IARC Monographs: 40 Years of evaluating carcinogenic hazards to humans. *Environ Health Perspect* 2015; 123:507–14; <http://dx.doi.org/10.1289/ehp.1409149>
319. Fitzgerald NR, Flanagan WM, Evans WK, Miller AB. Eligibility for low-dose computerized tomography screening among asbestos-exposed individuals. *Scand J Work Environ Health* 2015; 41(4): 407-412. doi:10.5271/sjweh.3496
320. Gocgun Y, Banjevic D, Taghipour S, Montgomery N, Harvey BJ, Jardine AK, Miller AB. Cost-effectiveness of breast cancer screening policies using simulation. *Breast* 2015; Apr 9. pii: S0960-9776(15)00080-6. doi: 10.1016/j.breast.2015.03.012.
321. Hassan LM, Mahmoud N, Miller AB, Iraj H, Mohsen M, Majid J, Mohammad Reza SM, Mojgan M. Evaluation of effect of self-examination and physical examination on breast cancer. *The Breast* 2015; 24: 487-490. <http://dx.doi.org/10.1016/j.breast.2015.04.011>.
322. Coldman AJ, Phillips N, Brisson J, Flanagan W, Wolfson M, Nadeau C, Fitzgerald N, Miller AB. Using the Cancer Risk Management Model to evaluate colorectal cancer screening options for Canada. *Curr Oncol*, 2015 Apr; 22(2):e41-50. doi: 10.3747/co.22.2013.
323. Koushik A, Wang M, Anderson KE, van den Brandt P, Clendenen TV, Eliassen AH, Freudenheim JL, Genkinger JM, Håkansson N, Marshall JR, McCullough ML, Miller AB, Robien K, Rohan TE, Schairer C, Schouten LJ, Tworoger SS, Wang Y, Wolk A, Zeleniuch-Jacquotte A, Smith-Warner SA. Intake of vitamins A, C, and E and folate and the risk of ovarian cancer in a pooled analysis of 10 cohort studies. *Cancer Causes Control* 2015; 26 (9): 1315-1327.

324. Miller AB, Gribble S, Nadeau C, Asakawa K, Flanagan WM, Wolfson M, Coldman A, Evans WK, Fitzgerald N, Lockwood G, Popadiuk C. Evaluation of the natural history of cancer of the cervix, implications for prevention. The Cancer Risk Management Model (CRMM) – Human papillomavirus and cervical components. *Journal of Cancer Policy* 2015; 4: 1-6.
325. Collaborative Group on Epidemiological Studies on Endometrial Cancer (AB Miller, collaborator). Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. *Lancet Oncol* 2015; 16 (9): 1061-1070.
326. Prorok PC, Kramer BS, Miller AB. Study designs for determining and comparing sensitivities of disease screening tests. *J Med Screen* 2015; 212 (4): 213-220. doi: 10.1177/0969141315600003
327. Miller AB, Feld F, Fontana R, Gohagan JK, Jatoi I, Lawrence W Jr., Miller A, Prorok PC, Rajput A, Sherman M, Welch G, Wright P, Yurgalevitch G, Albertsen P. Changes in and Impact of the Death Review Process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Reviews on Recent Clinical Trials* 2015; 10: 206-211.
328. Miller AB, Harrirchi I, Lotfi MH, Noori M, Mirzaei M, Jafarizadea M, Sadeghian MR, Minosepehr M. Yazd Breast Cancer Project Profile; A Community Based Trial for the Evaluation of Self-Examination and Physical Examination of the Breast Cancer Disease. *Iran J Med Sci.* 2015; 40(6): 531-536.
329. Goffin JR, Flanagan WM, Miller AB, Fitzgerald NR, Memon S, Wolfson MC, Evans WK. Cost-effectiveness of Lung Cancer Screening in Canada. *JAMA Oncol.* 2015; 1(6): 807-813.
330. Morgan LL, Miller AB, Sasco A, Davis DL. Mobile phone radiation causes brain tumors and should be classified as a probable human carcinogen (2A) (review). *Int J Oncol.* 2015; 46:1865-71.
331. Bleyer A, Baines C, Miller AB. Impact of screening mammography on breast cancer mortality. *Int J Cancer* 2016; 138(8): 2003-2012.
332. Popadiuk C, Gauvreau CL, Bhavsar M, Nadeau C, Asakawa K, Flanagan WM, Wolfson MC, Coldman AJ, Memon S, Fitzgerald N, Lacombe J, Miller AB. Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada. *Curr Oncol.* 2016; 23(S1): S56-S63.
333. Marcus PM, Doria-Rose VP, Gareen IF, Brewer B, Clingan K, Keating K, Rosenbaum J, Rozjabek HM, Rathmell J, Sicks J, Miller AB. Did death certificates and a death review process agree on lung cancer cause of death in the National Lung Screening Trial? *Clinical Trials*; 2016: 1-5. DOI: 10.1177/1740774516638345.
334. Portier CJ, Armstrong BK, Baguley BC, Baur X, Belyaev I, Bellé R, Belpoggi F, Biggeri A, Bosland MC, Bruzzi P, Budnik LT, Bugge MD, Burns K, Calaf GM,

- Carpenter DO, Carpenter HM, López-Carrillo L, Clapp R, Cocco P, Consonni D, Comba P, Craft E, Dalvie MA, Davis D, Demers PA, De Roos AJ, DeWitt J, Forastiere F, Freedman JH, Fritschi L, Gaus C, Gohlke JM, Goldberg M, Greiser E, Hansen J, Hardell L, Hauptmann M, Huang W, Huff J, James MO, Jameson CW, Kortenkamp A, Kopp-Schneider A, Kromhout H, Larramendy ML, Landrigan PJ, Lash LH, Leszczynski D, Lynch CF, Magnani C, Mandrioli D, Martin FL, Merler E, Michelozzi P, Miligi L, Miller AB, Mirabelli D, Mirer FE, Naidoo S, Perry MJ, Petronio MG, Pirastu R, Portier RJ, Ramos KS, Robertson LW, Rodriguez T, Rössli M, Ross MK, Roy D, Rusyn I, Saldiva P, Sass J, Savolainen K, Scheepers PTJ, Sergi C, Silbergeld EK, Smith MT, Stewart BW, Sutton P, Tateo F, Terracini B, Thielmann HW, Thomas DB, Vainio H, Vena JE, Vineis P, Weiderpass E, Weisenburger DW, Woodruff TJ, Yorifuji T, Yu IJ, Zambon P, Zeeb H, Zhou S-F. Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA). *J Epidemiol Community Health* 2016; doi:10.1136/jech-2015-207005.
335. Lujan-Barroso L, Zhang W, Olson SH, Gao Y-T, Yu H, Baghurst PA, Bracci PM, Bueno-de-Mesquita B, Foretová L, Gallinger S, Holcatova I, Janout V, Ji B-T, Kurtz RC, La Vecchia C, Lagiou P, Donghui Li D, Miller AB, Serraino D, Zatonski W, Risch HA, Duell EJ. Menstrual and Reproductive Factors, Hormone Use, and Risk of Pancreatic Cancer. Analysis From the International Pancreatic Cancer Case–Control Consortium (PanC4). *Pancreas* 2016;45(10):1401-1410.
336. Evans WK, Flanagan WM, Miller AB, Goffin JR, Memon S, Fitzgerald N, Wolfson MC. Implementing low-dose computed tomography screening for lung cancer in Canada: implications of alternative at-risk populations, screening frequency, and duration. *Curr Oncol.* 2016 June;23(3):e179-e187.
337. Shaevitch D, Taghipour S, Miller AB, Montgomery N, Harvey B. Tumor size distribution of invasive breast cancers and the sensitivity of screening methods in the Canadian National Breast Screening Study. *Journal of Cancer Research and Therapeutics* (accepted 2016)
338. Taghipour S, Caudrelier LN, Miller AB, Harvey BJ. Modelling and Validating Invasive Breast Cancer Progression in Women in the Study and Control Groups of the CNBSS I and II. *Medical Decision Making* 2016; DOI: 10.1177/0272989X16660711.
339. Baines CJ, To T, Miller AB. Revised estimates of overdiagnosis from the Canadian National Breast Screening Study. *Preventive Medicine* 2016; 90: 66–71.
340. Coldman A, Flanagan W, Nadeau C, Wolfson M, Fitzgerald N, Memon S, Gauvreau C, Miller A, Earle C. Projected effect of fecal immunochemical test threshold for colorectal cancer screening on outcomes and costs for Canada using the OncoSim microsimulation model. *Journal of Cancer Policy* 2017; 13: 38–46.
341. Gauvreau CL, Fitzgerald NR, Memon S, Flanagan WM, Nadeau C, Asakawa K, Garner R, Miller AB, Evans WK, Popadiuk CM, Wolfson M, Coldman AJ. The OncoSim

model: development and use for better decision-making in Canadian cancer control. *Curr Oncol.* 2017;24(6):401-406.

342. Miller AB. The role of screening mammography in the era of modern breast cancer treatment. *Climacteric* 2018; 21:3, 204-208, DOI: 10.1080/13697137.2017.1392503
343. Coldman A, Pader J, Gauvreau C, Memon S, Fitzgerald N, Flanagan W, Nadeau C, Earle C, Wolfson M, Miller A, Lacombe J. Simulating Results from Trials of Sigmoidoscopy Screening Using the OncoSim Microsimulation Model. *Journal of Cancer Policy* 2018; 15:52-58. <https://doi.org/10.1016/j.jcipo.2017.12.006>
344. Villeneuve PJ, Goldberg MS, Crouse DL, To T, Weichenthal SA, Wall C, Miller AB. Residential exposure to fine particulate matter air pollution and incident breast cancer in a cohort of Canadian women. *Environmental Epidemiology* 2018; 2:e021, DOI: 10.1097/EE9.000000000000021.
345. Miller AB, Morgan LL, Udasin I, Davis DL. Cancer Epidemiology Update, following the 2011 IARC Evaluation of Radiofrequency Electromagnetic Fields (Monograph 102). *Environmental Research* 2018; 167:673-83. <https://doi.org/10.1016/j.envres.2018.06.043>
346. Burnet R, Chen H, Szyszkowicz M, Fann N, Hubbell B, Pope CA, Apte JS, Brauer M, Cohen A, Weichenthal S, Coggins J, Di Q, Brunekreef B, Frostad J, Lim SS, Kan H, Walker KD, Thurston GD, Hayes RB, Lim CC, Turner MC, Jerrett M, Krewski D, Gapstur SM, Diver WR, Ostro B, Goldberg D, Crouse DL, Martin RV, Peters P, Pinault LP, Tjepkema M, van Donkelaar A, Villeneuve PJ, Miller AB, Yin P, Zhou M, Wang L, Janssen NAH, Marra M, Atkinson RW, Tsang H, Thach TQ, Cannon JB, Allen RT, Hart JE, Laden F, Cesaroni G, Forastiere F, Weinmayr G, Jaensch A, Nagel G, Concini H, Spadaro JV. Global estimates of mortality associated with long-term exposure to outdoor fine particulate matter. *PNAS* 2018; doi/10.1073/pnas.1803222115.
347. Jatoi I, Anderson WF, Miller AB, Brawley OW. The history of cancer screening. *Current Problems in Surgery* 2019; 56:138–163.
348. Becker N, Motsch E, Trotter A, Heussel CP, Dienemann H, Schnabel PA, Kauczor H-U, Maldonado SG, Miller AB, Kaaks R, Delorme S. Lung cancer mortality reduction by LDCT screening—Results from the randomized German LUSI trial. *Int. J. Cancer* 2019; 00: 00–00.

Non-peer reviewed

349. Miller AB (for T Parkinson) Budd-Chiari Syndrome. *Proc. Roy. Soc. Med.* 1961; 54: 229-232.
350. Miller AB. Thiacetazone Toxicity, a general review. *Tubercle, Lond.*, 1968: 49: March Supplement, 54-56.

351. Miller AB. Early detection and Mass Screening for Cancer. Canadian Family Physician: August 1972: 76.
352. Miller AB. Evaluation of Screening for Carcinoma of the Cervix. Modern Medicine of Canada 1973; 28:1067-1069.
353. Miller AB. Epidemiology: Problems in the Study of Cancer of Low Incidence and the need for Collaboration. J Natl Cancer Inst 1975; 54:299-302.
354. Miller AB. Role of nutrition in the etiology of breast cancer. Cancer 1977; 39:2704-2708.
355. Miller AB. The etiology of bladder cancer from the epidemiological viewpoint. Cancer Research 1977; 37:2939-2942.
356. Miller AB. Present status of breast cancer screening. (Editorial) CMA Journal 1977; 117:845-846.
357. Miller AB. Epidemiology of Colorectal Cancer. Canad. J. Surgery 1978; 21:209-210.
358. Miller AB. Non-Hodgkin's Lymphomas (Editorial). CMA Journal 1978; 119:401-402.
359. Miller AB. Mammography: An Epidemiologist's Critique, CMA Journal 1979; 120:1372-1373.
360. Miller AB. Familial risk of Cancer (Editorial) CMA Journal 1979; 121:505-509.
361. Miller AB. Epidemiology of the ten most common neoplasms. Can. Fam. Physician 1979; 30:1059-1064.
362. Miller AB. Methodologic Considerations for trials of lung cancer prophylaxis. CMA Journal 1980; 122:776-779.
363. Miller AB, Gori GB, Kunze M et al. Nutrition and Cancer. Preventive Medicine 1980; 9:189-196.
364. Miller AB. Identification of adults at high risk of lung cancer. CMA Journal 1980; 122:985-987.
365. Miller AB. Breast Cancer. Cancer 1981; 47:1109-1113.
366. Miller, A.B. Epidemiology of gastrointestinal cancer. Comprehensive Therapy 1981; 7:53-58.
367. Miller, A.B. The National Breast Screening Study: an opportunity for family physicians. Can. Fam. Physician. 1982; 28:369-372.
368. Baines, C.J., Miller, A.B. The Canadian National Breast Screening Study: Why it deserves support. Can. Fam. Physician. 1982; 28:481-485.
369. Miller, A.B. Obesity and cancer of endocrine related organs. Reviews on Endocrine Related Cancer 1982; 13:19-24.

370. Howe GR, Miller AB, Sherman GJ. Breast cancer mortality following fluoroscopic irradiation in a cohort of tuberculosis patients. *Cancer Detection and Prevention* 1982; 5(2): 175-178.
371. Miller AB, van Slooten EA. Screening and diagnosis in breast cancer; workshop report. *Eur. J. Cancer Clin. Oncol.* 1983; 19:1711-1716.
372. Miller AB Trends in cancer mortality and epidemiology. *Cancer* 1983; 51: 2413-2418.
373. Taft P, Meek ME, Wigle DT, Meranger JC, Miller A. Asbestos in Drinking Water. *Critical Reviews in Environmental Control* 1984; 14(2):151-197.
374. Miller AB Routine mammography and the National Breast Screening Study. (Editorial) *Can. Med. Assoc. J.* 1984; 130:259-260.
375. Miller AB. The Information Explosion. The role of the epidemiologist. *Cancer Forum.* 1984; 8:67-75.
376. Miller AB. Synthesis of papers on biological monitoring, case studies in screening, and social and economic issues. *J. Occup. Med.* 1986; 28:782-788.
377. Miller AB. Screening for breast cancer: A review. *Eur. J. Cancer Clin. Oncol.* 1988; 24:49-53.
378. Miller AB. Future plans for cancer control. 1988; *JAMA* 259:1706-1708.
379. Miller AB. Cervical Cancer Screening: A time for reappraisal in Canada? *Can J Pub Hlth* 1988; 79:90-91.
380. Miller AB. Screening for cancer. *West J Med* 1988; 149:718-722.
381. Miller AB. Diet and Cancer. A review. *Review in Oncology* 1990; 3:87-95.
382. Miller AB. Breast Cancer Screening: Who should be included? *J Gen Intern Med* 1990; 5:519-522.
- 383.** Miller AB. Commentary on the working group report on passive smoking. *Clinical and Investigative Medicine* 1990; 13:45-46.
384. Miller AB, Baines CJ, Sickles EA. Canadian National Breast Screening Study. *Am J Roentgenology* 1990; 155:1133-1134.
385. Miller AB. The role of early diagnosis and screening in oncology. *Diagnostic Oncology* 1991; 1:19-27.
386. Miller A.B. Epidemiology, prevention and prognostic factors in lung cancer. *Current Opinion in Oncology* 1991; 3:282-287.
387. Swenerton KD, Fugere P, Miller AB, MacLusky M. Menopausal progestins and breast cancer. *Journal SOGC.* June/July 1991, pp 7-9.
388. Miller AB, Anderson G, Brisson J, Laidlaw J, le Pitre N, Malcolmson P, Mirwaldt P, Stuart G, Sullivan W. Report of a National Workshop on Screening for Cancer of the Cervix. *Can Med Ass J* 1991; 145:1301-1325.

389. Miller AB. Epidemiology, prevention, prognostic factors and natural history of lung cancer. *Current Opinion in Oncology*. 1992; 4:286-291.
390. Miller AB. Screening and treatment of screen-detected cancer. *Eur J Cancer* 1992; 28:617-619.
391. Miller AB. Planning cancer control strategies. *Chronic Diseases in Canada* 1992; 13, Supplement 1.
392. Miller AB. The cost-effectiveness of cervical cancer screening. *Ann Intern Med* 1992; 117:529-530.
393. Miller AB. The role of screening in the fight against breast cancer. *World Health Forum*, 1992; 13:277-285.
394. Carlo GL, Cole P, Miller AB, Munro IC, Soloman KR, Squire RA. Review of a study reporting an association of 2,4 dichlorophenoxyacetic acid and canine malignant lymphoma: report of an expert panel. *Regulatory Toxicology and Pharmacology* 1992; 16: 245-252.
395. Miller AB. Response from the author. *Can J Pub Hlth* 1993; 84:21-22.
396. Miller AB. Implications of the National Breast Screening Study. *Can J Oncol* 1993; 3:189-192.
397. Miller AB. Prospects and controversies surrounding early breast cancer detection. *Cancer Research, Therapy and Control* 1993; 3:227-232.
398. Miller AB. General principles of early detection of cancer. *Oncore Ontario* 1993; 1: 8-14.
399. Miller AB. The costs and benefits of breast cancer screening. *Am J Prev Med* 1993; 9:175-180.
400. Miller AB. Canadian contributions to cancer control. *Can J Oncology* 1994; 4: 238-242.
401. Miller AB. How do we interpret the "Bad News" about cancer? *JAMA* 1994; 271:468.
402. Miller AB. Diet and the prevention of chronic diseases in the female patient. *Treating the Female Patient* 1994; 8:4-11.
403. Miller AB. Current results of research in breast cancer screening. *Chronic Diseases in Canada* 1994; 15:S7-S11.
404. Miller AB. Hospital or population controls? It depends on the question. *Preventive Medicine* 1994; 23:263-266.
405. Miller AB. Mammography screening controversies. *Cancer Detection and Prevention* 1994, 18:305-311.
406. Miller AB. An epidemiological perspective on cancer screening. *Clinical Biochemistry* 1995; 28:41-48.

407. Miller AB. La deteccion temprana y el tamizaje en el control del cancer. Boletin de la Oficina Sanitaria Panamericana 1995; 118:80-83.
408. Miller AB. The benefits and pitfalls of cancer screening. Helix 1995; IV:34-35.
409. Miller AB. Reducing colorectal cancer mortality - What strategy is best? Canadian Journal of Geriatrics 1995, 11:21-26.
410. Miller AB. Editorial: Failures of Cervical Cancer Screening. Am J Pub Hlth 1995; 85:761-762.
411. Miller AB. Screening for gastrointestinal cancer. Current Opinion in Oncology 1995; 7:373-376.
412. Miller AB. Perspectives on cancer prevention. Risk Analysis 1995; 15:655-660.
413. Miller AB. The Esserman/Kerlikowske article reviewed. Oncology 1996; 10:375-376.
414. Miller AB, Robles SC. Workshop on screening for cancer of the uterine cervix in Central America. Bull Pan Am Hlth Org 1996; 30:397-408.
415. Miller AB. The King/Schottenfeld article reviewed. Oncology 1996; 10:471-472.
416. Miller A, To T, Wall C. Technical report on the epidemiological study on the long-term effects of exposure to 60 hertz electric and magnetic fields - Ontario Hydro sectorial analysis -. Available from Ontario Hydro, 1996 b
417. Miller AB, Gaudette LA. Cancer of the respiratory system in Circumpolar Inuit. Acta Oncol 1996; 35: 571-576.
418. Miller AB, Gaudette LA. Breast cancer in Circumpolar Inuit, 1969-1988. Acta Oncol 1996; 35: 577-580.
419. Aronson KJ, Miller AB and eight collaborators. Environmental risk factors for breast cancer (Abstract). Epidemiology 1996; 7(Supplement):S38.
420. Miller AB, Gaudette LA. Cancers of skin, bone, connective tissues, brain, eye, thyroid and other specified and unspecified sites in Inuit. Acta Oncol 1996; 35: 607-616.
421. To T, Miller, AB, Xie HX. Lead time estimation and it use in survival analyses as applied to the National Breast Screening Study. American Statistical Association 1996 Proceedings of the Epidemiology Section. American Statistical Association, Chicago, 1996; ISBN 1-883276-43-8; pp 479-484.
422. Miller AB. The public health basis of cancer screening: Principles and ethical aspects. Cancer Treatment and Research 1996; 86:1-7.
423. Miller AB. Chemoprevention of cancer. Australian Epidemiologist 1998; 5: 2-5.
424. Miller AB. The status of screening for cervical cancer. Cancer Strategy 1999; 1:5-7.
425. McCauley G, Miller AB, Green LM, Greenberg ML. Childhood cancer epidemiology/dosimetry study. CEA No. 272 T 746. Montreal, Canadian Electricity Association, December 1999.

426. Miller AB. Tobacco and cancer: what has been, and could be, achieved? *Cancer Strategy* 1999; 1:165-169.
427. Rohan TE, Jain M, Rehm JTMiller AB. Cigarette smoking and risk of death from colorectal cancer in women. *The Ontario Tobacco Research Unit Working Paper Series*, No. 55, June 2000.
428. Miller AB, Nettesheim P, Stewart BW. An International evaluation of the cancer-preventive potential of nine retinoids. *Asian Pacific Journal of Cancer Prevention* 2000; 1:195-202.
429. Vainio H, Miller AB, Bianchini F. An International Evaluation of the Cancer-preventive potential of sunscreens. *Int J Cancer* 2000, 88:838-842.
430. Miller AB. Organized breast cancer screening programs in Canada. *Can Med Ass J* 2000; 163:1150-1151.
431. Miller AB. Chemoprevention of cancer. *Asia Pacific Journal of Cancer Prevention* 2000; 1: Suppl. 21-24.
432. Miller AB, Yurgalevitch S, Weissfeld JL. Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. *Control Clin Trials* 2000; 21: 400S-406S.
433. Miller AB. Commentary: Natural history of cervical human papillomavirus infections. *Lancet* 2001; 357:1816.
434. Miller AB. Commentary: How do we decide at what age and at what frequency to screen for cancer of the cervix by cervical cytology? *Int J Cancer* 2001; 94:889-890.
435. Miller AB and Bartsch H. Editorial: Hair dye use and Bladder cancer. *Int J Cancer* 2001; 94:901-902.
436. Auvinen A, Alexander FE, de Koning HJ, Miller AB. Editorial: Should we start population screening for prostate cancer? Randomised trials are still needed. *Int J Cancer* 2002; 97:377-378.
437. Miller AB. Der natuerliche Verlauf einer Infektion der Cervix uteri mit humanen Papillomaviren. *Frauenarzt* 2002; 43: 686-690.
438. Miller AB. Editorial comment. The (in)efficiency of cervical screening in Europe. *Eur J Cancer* 2002; 38:321-326.
439. Miller AB. Review: Quality assurance in screening strategies. *Virus Research* 2002; 89:295-299.
440. Miller AB, Sankaranarayanan R, Bosch FX, Sepulveda S. Mini review. Can screening for cervical cancer be improved, especially in developing countries? *Int J Cancer* 2003; 107: 337-340.

441. Miller AB. Commentary [on “An intensive programme of instruction in breast self-examination did not reduce mortality from breast cancer”] re Thomas et al JNCI 2002; 94:1445-1457.
442. Vainio H, Miller AB. Primary and secondary prevention in colorectal cancer. Acta Oncol 2003; 42:809-815.
443. Miller AB. Commentary: A defence of the Health Insurance Plan (HIP) study and the Canadian National Breast Screening Study. Int J Epidemiol 2004; 33: 64-65.
444. Miller AB. Screening for Breast Cancer - is there an alternative to mammography? Asia Pacific Journal of Cancer prevention 2005; 6:83-86.
445. Strong K, Wald N, Miller A, Alwan A, on behalf of the WHO Consultation Group. Current concepts in screening for noncommunicable disease: World Health Organization Consultation Group Report on methodology of noncommunicable disease screening. J Med Screen 2005; 12:12-19.
446. Bartsch, H, Miller AB. Editor’s comments, “Epidemiologic studies of nutrition and cancer”. Int J Cancer 2005; 116:661.
447. Miller AB. Commentary. In: Insight on Cancer, Environmental Exposures and Cancer. Cancer Care Ontario. Volume 4, 2005; p 6-8
448. Miller AB. Editorial. Childhood cancer control. Is progress being made? Int J Cancer 2006; 118: 2651.
449. zur Hausen H, Bartsch H, Fusenig N, Doeberitz M von K, Kyewski B, Lichter P, Miller A. Conflicts of interest: The responsibility of the authors and editors of the *International Journal of Cancer*. Int J Cancer 2006; 119:2919.
450. Miller AB. Book review: Early breast cancer, from screening to multidisciplinary management. New Engl J Med 2006; 354:26-7.
451. Miller AB. Design of cancer screening trials/ randomized trials for evaluation of cancer screening. World Journal of Surgery 2006; 30: 1152-1162.
452. Miller AB. Early detection of breast cancer in the emerging world. Zentralbl Gynakol 2006; 128: 191-195.
453. Miller AB. Commentary: Implications of the frequent occurrence of occult carcinoma of the prostate. Int J Epidemiol 2007; 36: 282-284.
454. Miller AB. Editorial: Environment and Cancer - How can the Ecological Study help us? Prev Med 2007; 45:325-326.
455. Little J, McLaughlin J, Miller AB. Editorial: Leukemia in young children living in the vicinity of nuclear power plants. Int J Cancer 2008; 122:x-xi.
456. Miller AB. Implementation of colon cancer screening: Techniques, costs and barriers. Gastroenterology Clinics of North America 2008; 37:83-95.

457. Miller AB. Book Review: Screening, Evidence and Practice. Bull. WHO 2008; 86:320.
458. Miller, A. Practical applications for clinical breast examination (CBE) and breast self-examination (BSE) in screening and early detection of breast cancer. Breast Care 2008; 3:17-20.
459. Mousavi SM, Harirchi I, Ebrahimi M, Mohagheghi MA, Montazeri A, Jarrahi AM, Gouya MM, Miller AB. Screening for breast cancer in Iran: a challenge for health policy makers. Breast J. 2008;14(6):605-6. doi: 10.1111/j.1524-4741.2008.00662.x.
460. Miller AB. Commentary. Breast cancer and passive smoking. Prev Med 2008; 46: 497-498.
461. Miller AB. Screening for cervical cancer and cancer precursors in Canada. HPV Today 2008; 15:5.
462. Miller AB. Commentary. The place for routine mammography screening, commencing at age 40. Prev Med 2008; 47: 485-486.
463. Miller AB. Cervical cancer in rural India. Nature Reviews Clinical Oncology, 2009; 6:384-5.
464. Miller AB. Re: Doubt is Their Product: How Industry's Assault on Science Threatens Your Health by David Michaels, PhD, MPH (Oxford University Press, 2008). Prev Med. 2009; 49: 272-3.
465. Miller AB. The case against PSA-based screening. Cancer Prevention (A National Newsletter from New York Presbyterian Hospital) 2010; 14: 7.
466. Miller AB. Conundrums in screening for cancer. Mini Review. Int J Cancer 2010; 126: 1039-1046.
467. Miller AB, Green LM. Electric and magnetic fields at power frequencies. Chronic Diseases in Canada 2010; 29: Supplement, 69-83.
468. Miller AB. Screening for breast cancer in the Eastern Mediterranean Region. Eastern Mediterranean Health Journal 2010; 10: 1022-1024.
469. Miller AB. Breast Cancer Screening. Introduction. Preventive Medicine 2011; 53: 99.
470. Miller AB, Baines CJ. The role of clinical breast examination and breast self-examination. Preventive Medicine 2011; 53: 118-20.
471. Miller AB. Breast cancer screening: Commentary and conclusions. Preventive Medicine 2011; 53: 147-8.
472. Miller AB. Editorial: New Data on Prostate-Cancer Mortality after PSA Screening. New Engl J Med 2012: 366 (11):1047-8.
473. Miller AB. Screening for lung cancer with low dose computerized tomography. Con. The Oncologist 2013; 18:897-899.

474. Miller AB. Does HPV vaccination prevent cervical cancer? *South Asian J Cancer* 2013;2:198-9.
475. Miller AB. Editorial: Digital Mammography. *JNCI Journal of the National Cancer Institute* 2014 106 (4): dju125
doi: 10.1093/jnci/dju125
476. Miller A. Re: "counterpoint: overdiagnosis in breast cancer screening". *J Am Coll Radiol.* 2014 Sep;11(9):923. doi: 10.1016/j.jacr.2014.05.013. Epub 2014 Jun 11.
477. Miller AB. Implications of the Canadian National Breast Screening Study. *Women's Health* 2014; 10:345-7.
478. [Alpers DH](#), [Bier DM](#), [Carpenter KJ](#), [McCormick DB](#), [Miller AB](#), [Jacques PF](#). History and impact of nutritional epidemiology. *Adv Nutr.* 2014 Sep;5(5):534-6.
479. Jatoi I, Miller AB. Breast Cancer Screening in Elderly Women Primum Non Nocere. *JAMA Surgery* 2015; 150 (12): 1107-8. doi:10.1001/jamasurg.2015.2663.
480. Hemminki K, Miller AB. Special section editorial: Cancer incidence in five continents including Africa. *Int J Cancer* 2015; 137: 2043-2044.
481. Lyons G, Sankaranarayanan R, Miller AB, Slama S. Scaling up cancer care in the WHO Eastern Mediterranean Region. *East Mediterr Health J.* 2018;24(1):104–110. <https://doi.org/10.26719/2018.24.1.104>
482. Miller AB. Editorial: Improving surveillance following treatment for lung cancer. *J Thoracic Oncology* 2019; 14(6): 955.

Books and Reports

483. Miller AB (ed). *Screening in Cancer. UICC Technical Report Series - Volume 40.* Geneva, International Union Against Cancer, 1978.
484. WHO Handbook for Reporting Results of Cancer Treatment (Miller AB, Member of Writing Committee, Rapporteur Turin meeting, Chairman Brussels meeting). Geneva, World Health Organization, 1979. <http://whqlibdoc.who.int/publications/9241700483.pdf>
485. Committee on Diet Nutrition and Cancer (Miller AB, Member). *Diet, Nutrition and Cancer.* National Academy Press, Washington, D.C., 1982.
486. Committee on Diet Nutrition and Cancer (Miller AB, Member). *Diet, Nutrition and Cancer: Directions for Research.* National Academy Press, Washington, D.C., 1983.
487. National Research Council. *Assigned share for radiation as a cause of cancer.* Washington, D.C. National Academy Press 1984 (Miller, AB, Committee member).
488. Prorok PC, Miller AB (eds). *Screening for cancer. I - General principles on evaluation of screening for cancer and screening for lung, bladder and oral, cancer.* UICC technical report series - Volume 78. Geneva, International Union Against Cancer, 1984.

489. Miller AB (ed). Screening for cancer. Orlando Fla, Academic Press, Inc, 1985.
490. Hakama M, Miller AB, Day NE (eds). Screening for cancer of the uterine cervix. IARC Scientific publications no. 76. Lyon, International Agency for Research on Cancer, 1986.
491. Chamberlain J, Miller AB (eds). Screening for gastro-intestinal cancer. Hans Huber, Toronto, 1988.
492. Day NE, Miller AB (eds). Screening for breast cancer. Hans Huber, Toronto, 1988.
493. Miller AB (ed). Diet and the aetiology of cancer. ESO Monographs. Berlin, Springer-Verlag, 1989.
494. Committee on Diet and Health (Miller AB, Member). Diet and health. Implications for reducing chronic disease risk. National Research Council. Washington DC, National Academy Press, 1989.
495. Tomatis L, Aitio A, Day NE, Heseltine E, Kaldor J, Miller AB, Parkin DM, Riboli E (eds). Cancer: causes, occurrence and control. IARC Scientific publications no. 100. Lyon, International Agency for Research on Cancer, 1990.
496. Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC (eds). Cancer Screening, Cambridge, Cambridge University Press, 1991.
497. Committee on Environmental Epidemiology (Miller AB, Chairman). Environmental epidemiology. Public health and hazardous wastes. National Research Council. Washington DC, National Academy Press, 1991.
498. Miller AB. Cervical cancer screening programmes. Managerial Guidelines. Geneva, World Health Organization, 1992.
499. Miller AB, Stjernsward J (eds). National cancer control programmes. Policies and managerial guidelines. (Preliminary edition) Geneva, World Health Organization, 1992.
500. IARC Monographs on the evaluation of carcinogenic risks to chemicals. Volume 56. Some naturally occurring substances: Food items and constituents, heterocyclic amines and mycotoxins. (Miller AB, Chairman of working group). Lyon, International Agency for Research on Cancer, 1993.
501. IARC Monographs on the evaluation of carcinogenic risks to chemicals. Volume 59. Hepatitis viruses. (Miller AB, Chairman of working group). Lyon, International Agency for Research on Cancer, 1994.
502. Miller AB, Stjernsward J (eds). National cancer control programmes. Policies and managerial guidelines. Geneva, World Health Organization, 1995.
503. Ontario Task Force on the Primary Prevention of Cancer (Miller AB, Chairman). Recommendations for the primary prevention of cancer. Toronto: Queen's Printer for Ontario, 1995.

504. Miller AB (ed). *Advances in Screening for Cancer*. Boston, Kluwer Academic Publishers. 1996.
505. Committee on Environmental Epidemiology (Miller AB, Chairman), and Commission on Life Sciences, National Research Council. *Environmental Epidemiology. Volume 2. Use of the Gray Literature and Other Data in Environmental Epidemiology*. Washington, DC, National Academy Press, 1997.
506. IARC Handbooks on Cancer Prevention, Vol 1, *Some Non-steroidal Anti-inflammatory Agents*. (Miller AB, Chairman of Working Group). Lyon, International Agency for Research on Cancer, 1997.
507. IARC Handbooks on Cancer Prevention, Vol 4, *Retinoids*. (Miller AB, Responsible Officer) Lyon, International Agency for Research on Cancer, 1999.
508. Miller AB, Bartsch H, Boffetta P, Dragsted L, Vainio H (Eds). *Biomarkers in Cancer Chemoprevention*. IARC Scientific Publications No. 154. Lyon, International Agency for Research on Cancer, 2001.
509. IARC Handbooks on Cancer Prevention, Vol 5, Sunscreens. (Miller AB, Responsible Officer) Lyon, International Agency for Research on Cancer, 2001.
510. *National Cancer Control Programmes. Policies and Managerial Guidelines*. 2nd Edition. A.B.Miller with Ken Stanley providing editorial guidance. [I delivered the manuscript to WHO, prior to their standard editorial process.] Geneva. Geneva, World Health Organization, 2002.
511. IARC Handbooks on Cancer Prevention, Vol 6, *Weight control and physical activity*. (Miller AB, Member of secretariat) Lyon, IARC Press, 2002.
512. IARC Handbooks on Cancer Prevention, Vol 7, *Breast cancer screening*. (Miller AB, Chairman of Epidemiology Working Group) Lyon, IARC Press, 2002.
513. *Report of a WHO Consultation. Cervical screening in developing Countries*. (Miller, AB, Chairman of Cytology subgroup, and Editor of report). Geneva, World Health Organization, 2002.
514. IARC Handbooks on Cancer Prevention, Vol 8, *Fruits and vegetables*. (Miller AB, Chairman of Epidemiology Working Group) Lyon, IARC Press, 2003.
515. *Progress Report on Cancer Control in Canada* (Anthony Miller and Howard Morrison, Scientific Editors). Health Canada, Ottawa, Publication No. 5040, 2004.
516. IARC Handbooks on Cancer Prevention, Vol 9, *Cruciferous vegetables, Isothiocyanates and Indoles*. (Miller AB, Chairman of Epidemiology Working Group) Lyon, IARC Press, 2004.
517. IARC Handbooks on Cancer Prevention, Vol 10, *Cervix cancer screening*. (Miller AB, Vice-Chairman and Chairman of Epidemiology Working Group) Lyon, IARC Press, 2005.

518. WHO Guide for Effective Programmes. Cancer Control. Knowledge into Action: Planning. Scientific Editor A.B. Miller. Geneva, World Health Organization, 2006.
519. WHO Guide for Effective Programmes. Cancer Control. Knowledge into Action: Early Detection. Scientific Editor A.B. Miller, and coordinator of module. Geneva, World Health Organization, 2007.
520. WHO Guide for Effective Programmes. Cancer Control. Knowledge into Action: Palliative Care. Scientific Editor A.B. Miller. Geneva, World Health Organization, 2007.
521. Rapport du comité scientifique constitué par l'institut national de santé publique du Québec (Anthony Miller, President). Pertinence et faisabilité d'un programme de dépistage du cancer colorectal au Québec. Institut national de santé publique du Québec, October 2008.
522. Collishaw NE, Boyd NF, Cantor KP, Hammond SK, Johnson KC, Millar J, Miller AB, Miller M, Palmer JR, Salmon AG, Turcotte F. Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk. Toronto, Canada: Ontario Tobacco Research Unit, OTRU Special Report Series, April 2009.
523. Miller AB (Guest Editor). Special Issue: Breast cancer screening. Preventive Medicine 2011; 53: 99-148.
524. Miller AB (Editor). Epidemiologic Studies in Cancer Prevention and Screening. Statistics for Biology and Health; Volume 79. New York, Springer Verlag, 2013. ISBN: 978-1-4614-5585-1 (Print) 978-1-4614-5586-8 (Online).
525. IARC Monographs on the evaluation of carcinogenic risks to chemicals. Volume 100A. Pharmaceuticals. (Miller AB, Co-Chairman of working group). Lyon, International Agency for Research on Cancer, 2012.
526. Miller AB. What Causes Cancer? What we know and what it means. Victoria BC, Friesen Press, 2014. (url: <http://www.friesenpress.com/bookstore/title/119734000012176596>).
527. IARC Handbooks of Cancer Prevention. Volume 15 Breast Cancer Screening. (Miller AB, Member of Working Group). Lyon, International Agency for Research on Cancer, 2016.
528. WHO Guide to Early Cancer Diagnosis. Miller AB, Technical Editor. Geneva, World Health Organization, 2017.

Chapters in books

529. Miller AB. Controlled trials in Cancer of the Lung. (1967) Transactions of the International Chest and Heart Conference, Eastbourne, p. 75.

530. Miller AB. Ambulatory Chemotherapy in the technically advanced countries in relation to experience in the developing countries (1967). Transactions 5th International Congress of Chemotherapy, Vienna, p. 517.
531. Miller AB. A sampling survey of the results of treatment achieved by the routine services in Kenya (1970) Proc. XXth Int. Tuberculosis Conf. N.Y., p. 94, Exerpta Medica Foundation.
532. Fox W, Miller AB. The organization of Cooperative Controlled Clinical Trials (1970) In Modern Radiotherapy, Vol.2, Carcinoma of the Bronchus. Butterworths, London.
533. Miller AB. Evaluation of Mass Screening Programmes for Carcinoma of the Cervix. Proc. XI, Int. Cancer Congress - Florence (1974) Vol: 4, pp. 204-281, Exerpta Media, 1975.
534. Miller AB. Opportunities for Cancer Etiology. Persons at High Risk of Cancer: an approach to Cancer Etiology and Control (1975) Academic Press Inc. pp. 521-526.
535. Miller AB. The Epidemiological Basis of Public Policy. Proceedings of the 11th Canadian Cancer Research Conference, Toronto, May 1976, pages 2-12.
536. Miller AB. The Problem of Control Patients in Clinical Trials. Procs. International Symposium on the Present Status of BCG in Cancer Immunotherapy. Esterel Quebec, 1976, pp. 331-336.
537. Miller AB. Design and Problems Associated with the CRCC Clinical Trial of BCG and Lung Cancer. Procs. International Symposium on the Present Status of BCG in Cancer Immunotherapy. Esterel Quebec, 1976, pp. 201-205.
538. Miller AB. Economic Aspects of Screening for Cancer. Procs. Third International Symposium on Detection and Prevention of Cancer. New York, 1978, pp. 1225-1233.
539. Miller AB. The Epidemiology of Carcinoma of the Cervix, a review. In Burghardt, E., Holzel, E., and Jordan, J.A. (Eds). "Cervical Pathology and Colposcopy". Georg Thieme, Publishers, Stuttgart, 1978, pp. 103-111.
540. Miller AB. Risk benefit in mass screening programmes for breast cancer. Seminars in oncology, 5:351-359, 1978.
541. Magnus K, Miller AB. Methodology of controlled prophylactic trials in Canada. In UICC Technical Report Series, 1978. Volume 36: 97-128.
542. Miller AB. Screening for cancer of the cervix in Canada, Post Walton. In Miller AB, Ed. "Screening in Cancer". A report of a UICC International Workshop, Toronto, Canada, 1978. UICC Technical Report Series, 1978. Volume 40 pp. 73-92.
543. Miller AB. Public education in uterine cancer control. In: Advances in Medical Oncology, Research and Education. Vol. 8. Pergamon, Oxford. 1979 pp. 217-221.
544. Miller AB. Detection: Mass screening and high risk. In: Advances in Medical Oncology, Research and Education. Vol. 2. Pergamon, Oxford, 1979 pp. 105-109.

545. Miller AB. Bladder cancer - epidemiology. In: *Advances in Medical Oncology, Research and Education*. Vol. 11. Pergamon, Oxford, 1979. pp. 201-206.
546. Miller AB. Lifestyle factors in Human Cancer. In *Cancer: Achievements, Challenges and Prospects for the 1980's*. Vol. 1. Ed. J.H. Burchenal and H.F. Oettgen. Grune & Stratton. New York, 1980 pp 71-78.
547. Miller AB. Epidemiology and Etiology of lung cancer. In *Lung Cancer 1980*. Ed H.H. Hansen and M. Roth Excerpta Medica, Amsterdam, 1980 pp 9-26.
548. Miller AB. Breast Cancer etiologic influences. In *Breast Cancer New Concepts in Etiology and Control*. Academic Press, New York, 1980. pp 17-27.
549. Miller AB. Control of carcinoma of cervix by exfoliative cytology screening. In "Gynecologic Oncology", Copleston, M. Ed. Churchill, Livingstone, Edinburgh, 1981 pp 9-18.
550. Miller AB, Rawls WE. Epidemiology of gynecologic cancer. I cervix. In "Gynecologic Oncology", Copleston, M.Ed. Churchill Livingstone, Edinburgh, 1981 pp 9-18.
551. Miller AB. An evaluation of population screening for cervical cancer. In "Advances in Clinical Cytology". Koss LG, Coleman DV, Eds. Butterworths, London, 1981 pp 64-94.
552. Miller AB. Epidemiology of gastrointestinal cancer. In "Gastrointestinal Cancer." Strochlein JR, Romsdahl MM. Eds. Raven Press, New York, 1981, pp 31-40.
553. Miller AB. The Canadian experience of cervical cancer: Incidence trends and a planned natural history investigation. In "Trends in Cancer Incidence" Magnus K, Ed. Hemisphere publishing Corp. Washington, 1982, pp 311-320.
554. Miller AB. Fundamental issues in screening. In "Cancer Epidemiology and Prevention". Schottenfeld D and Fraumeni JF Jr. Eds. W.B. Saunders, Philadelphia, 1982 pp 1064-1074.
555. Miller AB and Van der Schueren E. Evaluation of diagnostic procedures and other aids to patient management. In "Evaluation of Methods of Treatment and Diagnostic Procedures in Cancer" (Grage TR et al, eds). UICC Technical Report Series Vol 70. International Union against Cancer, Geneva, 1982, pp101-119.
556. Miller AB and Saracci R. Some aspects of ethics in controlled trials. In "Evaluation of Methods of Treatment and Diagnostic Procedures in Cancer" (Grage TR et al, eds). UICC Technical Report Series Vol 70. International Union against Cancer, Geneva, 1982, pp121-139.
557. Miller AB. Nutritional Aspects of Human Carcinogenesis. In "Host Factors in Human Carcinogenesis" (H. Bartsch and B. Armstrong, eds.) IARC Scientific Publication No. 39. International Agency for Research on Cancer, Lyon, 1982, pp 177-192.

558. Miller AB. Evaluation of screening for cancer of the cervix and breast. Implications for cancer control. In "Issues in Cancer Screening and Communications" (Mettlin C and Murphy GP, eds). Alan A Liss Inc, New York, 1982, pp 41-54.
559. Miller AB. Coffee and Cancer. In "Carcinogens and Mutagens in the Environment" Vol. III Naturally occurring compounds. (HF Stich ed.). CRC Press. Boca Raton, Florida, 1983, pp 13-20.
560. Miller AB. Approaches to the control of breast cancer. In "Understanding Breast Cancer". Clinical and laboratory concepts. (MA Rich, JC Hager and P Furmanski, Eds.). Marcel Dekker Inc., New York, 1983 pp 3-25.
561. Miller AB. Epidemiology in the assessment of risk. In "Risk, Risque". Proceedings of a symposium on the assessment and perception of risk to human health in Canada. (JT Rogers and DV Bates, Eds.). Royal Society of Canada, pp 53-65, 1983.
562. Miller AB. Cancer of the colon and rectum. In "The Epidemiology of Cancer" (GJ Bourke, Ed.). Croon Helm, London, 1983 pp 145-161.
563. Miller AB, Choi BCK, Howe GR, Burch JD, Sherman GJ. Epidemiological assessment of risk to humans from exposure to nitrosamines. IARC Scientific Publication. No. 57, 1984, pp 929-936.
564. Roberts L. The Epidemiology of Diet and Cancer. Chapter 5 in Cancer Today, Origins, Prevention and Treatment. Washington DC, Institute of Medicine/National Academy Press, 1984, pp 49-61. Based on the presentation given at the 1983 Annual Meeting of the Institute of Medicine by Anthony B. Miller, National Cancer Institute of Canada, University of Toronto.
565. Miller AB. Principles of screening and of the evaluation of screening programs. In Miller AB ed. Screening for cancer. Academic Press Orlando pp 3-24, 1985.
566. Miller AB. Screening for cancer of the cervix. In Miller AB ed. Screening for cancer, Academic Press Orlando pp 295-323, 1985.
567. Miller AB. Screening for cancer of the breast. In Miller AB ed. Screening for cancer, Academic Press Orlando pp 325-345, 1985.
568. Miller AB. Obesity and Cancer. In Frankle RT, Dwyer J, Morague L and Owen A. Dietary treatment and prevention of obesity. John Libbey, London, pp 155-166, 1985.
569. Miller AB. Dietary Fat and Breast Cancer. In Dietary Fat and Cancer. Allan R Liss, Inc., New York, 1986, pp 17-32.
570. Miller AB. Overview: Diet and nutrition in the context of cancer epidemiology. In Genetic Toxicology of the Diet. Allan R Liss, Inc., New York, 1986, pp 275-285.
571. Miller, A.B. Epidemiology and prevention. In Breast Diseases. JB Lippincott Company, Philadelphia, 1986, pp 87-102.

572. Miller AB. Early detection of breast cancer. In *Breast Diseases*. JB Lippincott Company, Philadelphia, 1987, pp 122-134.
573. Miller AB. Approaches to cancer control in Canada and internationally. In *Advances in Cancer Control: The war on cancer...15 years of progress..* Alan R Liss, Inc., New York, 1987, pp 9-23.
574. Miller AB. Review of sigmoidoscopic screening for colorectal cancer. In Chamberlain J and Miller AB (eds.) *Screening for gastro-intestinal cancer*. Hans Huber, Toronto pp 3-7, 1988.
575. Miller AB. The Canadian National Breast Screening Study. In Day NE and Miller AB (eds.) *Screening for breast cancer*. Hans Huber, Toronto pp 51-58, 1988.
576. Miller AB. Mass screening programmes for cancer of the breast. *Balliere's Clinical Oncology*. 2:139:153, 1988.
577. Miller AB and Schechter MT. Calculating a woman's degree of risk. In Stoll BA (ed) *Women at high risk of breast cancer*. Kluwer Academic Publishers, Dordrecht, 1989, pp 75-83.
578. Miller AB. Cancer Screening. In De Vita VT, Hellman S, Rosenberg SA. (eds) *Cancer. Principles and Practice of Oncology*. 3rd Ed. Lippincott, Philadelphia 1989, pp 478-487.
579. Miller AB. The role of screening mammography in determining risk in breast lesions. In Regaz/Ariel (eds). *High Risk Breast Cancer*. Springer-Verlag, Berlin. 1989, pp 262-272.
580. Miller AB. Vitamins, minerals and other dietary factors. In Miller AB (ed). *Diet and the aetiology of cancer*. ESO Monographs. Berlin, Springer-Verlag, 1989, pp 39-54.
581. Miller AB. Early detection of breast cancer. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) *Breast Diseases*, second edition. Philadelphia, Lippincott, 1991; pp 215-228.
582. Miller AB, Baines CJ, To T and Wall C. The Canadian National Breast Screening Study. In *Cancer Screening*, Miller AB, et al (eds). Cambridge, Cambridge University Press, 1991, pp 45-55.
583. Miller AB, Knight J, Narod S. The Natural History of Cancer of the Cervix, and the implications for screening policy. In *Cancer Screening*, Miller AB et al (eds). Cambridge, Cambridge University Press, 1991 pp 144-152.
584. Miller AB. Issues in screening for prostate cancer. In *Cancer Screening*, Miller A.B. et al (eds). 1991, pp 289-293.
585. Miller AB. Epidemiology aspects of early detection programs. In *Cancer Diagnosis*, Bannasch P (ed). Berlin, Springer-Verlag, 1992, pp 237-249.

586. Miller AB. Control of carcinoma of cervix by exfoliative cytology screening. In Gynecologic Oncology, Coppleson M, Monaghan JM, Morrow CP, Tattersall MHN (eds). London, Churchill Livingstone, Vol 1, 1992, pp 543-555.
587. Miller AB. Epidemiology and etiology. In Surgical Gynecologic Oncology, Burghardt E et al (eds). Stuttgart, Georg Thieme Verlag, 1993; pp185-188.
588. Miller AB. Cancer Screening. In De Vita VT, Hellman S, Rosenberg SA (eds). Cancer. Principles and Practice of Oncology. 4th Ed. Lippincott, Philadelphia 1993, pp 564-573.
589. Miller AB. Mammography in women under 50. In Shapiro CL, Henderson IC (eds). New Directions in breast cancer research and therapeutics. Hematology/Oncology Clinics of North America; 8:#1:165-177, February 1994.
590. Miller AB. Potential impact of automation on Pap smear reading in developing countries. In Grohs HK, Hussain OAN (eds). Automated cervical cancer screening. New York, Igaku-Shoin, 1994, pp 338-344.
591. Miller AB. Review of extant community-based epidemiologic studies on health effects of hazardous wastes. In Andrews JS et al, eds. Hazardous Waste and Public Health: International congress on the health effects of hazardous wastes. Princeton NJ, Princeton Scientific Publishing Co. Inc., 1994, pp 677-684.
592. Miller AB. Epidemiology. In Pearson FG et al, eds. Thoracic Surgery. New York, Churchill Livingstone, 1995, pp 648-661.
593. Miller AB. Role and limitations of mammography in screening. In Stoll BA, ed. Reducing breast cancer risk in women. Dordrecht, Kluwer Academic Publishers, 1995, pp 217-221.
594. Miller AB. Evaluation of risks associated with hazardous waste. In Bertollini R, Lebowitz MD, Saracci R and Savitz D, eds, Environmental Epidemiology. Boca Raton, Lewis Publishers, 1995, pp 49-62.
595. Miller AB. Screening for cervical cancer. In Rubin SC, Hoskins, WJ, eds. Cervical Cancer and Preinvasive Neoplasia. Philadelphia, New York, Lippincott-Raven, 1996, pp 13-25.
596. Miller AB. The public health basis of cancer screening: principles and ethical aspects. In Miller AB (ed). Advances in Screening for Cancer. Boston, Kluwer Academic Publishers. 1996, pp1-7.
597. Miller AB. Screening in developing countries: problems and opportunities. In Miller AB (ed). Advances in Screening for Cancer. Boston, Kluwer Academic Publishers. 1996, pp 183-189.
598. Miller AB. Fundamental issues in screening for cancer. In Schottenfeld D & Fraumeni JF, Jr. Cancer Epidemiology and Prevention, Second Edition. New York, Oxford, Oxford University Press, 1996, pp 1433-1452.

599. Miller AB, Baines CJ, Harvey BJ. Screening by breast self-examination. In Jatoi I (ed) Breast Cancer Screening. Austin Texas, Landes Biosciences, 1997 pp 81-96.
600. Miller AB. Chapter 33: Screening and Detection. In Bland KI and Copeland EM (eds). The Breast. Comprehensive management of benign and malignant diseases, Second Edition. Philadelphia, WB Saunders Company, 1998; pp 625-633.
601. Miller AB. Cervix cancer. In: Kramer BS, Gohagan JK, Prorok PC, (eds) Cancer Screening, Theory and practice. New York, Marcel Dekker, Inc; 1999; pp195-217.
602. Miller AB. Diet and Human Cancer. In: Proceedings of the Fourth Princess Chulabhorn International Science Congress. Chemicals in the 21st century. Chemicals for sustainable development. Bangkok, Thailand, Chulaborn Research Institute. 28 November-2 December, 1999; pp168-172.
603. Miller AB. Chemoprevention des Kolorektalkarzinoms. In: Metzger U (ed.) Darmkrebs: Fakten und Handlungsbedarf. Bern, Schweizerische Krebsliga. 2000; pp 25-28.
604. Miller A. The natural history of cancer of the cervix – implications for screening and management. In: Monsonego J (ed.) Eurogin 2000. Bologna, Monduzzi Editore, 2000; pp 47-53.
605. Miller A. Global cancer prevention strategies in the 21st century. In: Monsonego J (ed.) Eurogin 2000. Bologna, Monduzzi Editore, 2000; pp 101-108.
606. Miller AB. Breast screening. In: Nabholz J-M, Tonkin K, Aapro MS, Buzdar AU (eds). Breast cancer management. Application of evidence to patient care. London, Martin Dunitz, 2000; pp 527-536.
607. Miller AB. The natural history of cancer of the cervix – implications for screening. In: Gupta S, Sood OP (eds). Recent developments in the management of cancer of the uterine cervix. Proceedings of the Sixth Annual Ranxbury Science Foundation Symposium held in New Delhi on December 11, 1999. New Delhi, Ranxbury Science Foundation, 2000, pp3-7.
608. Miller AB, Borges AM. Intermediate histological effect markers for breast cancer. In: Miller AB, Bartsch H, Boffetta P, Dragsted L, Vainio H. Biomarkers in Cancer Chemoprevention. IARC Scientific Publications No. 154. Lyon, International Agency for Research on Cancer, 2001, pp 171-175.
609. Miller AB. Screening. In: Franco EL, Rohan, TE (eds). Cancer precursors. Epidemiology, detection and prevention. New York Berlin Heidelberg Springer-Verlag, 2002, pp 365-373.
610. Miller AB, Goel V. Screening. In: Detels, R, McEwen J, Beaglehole R, Tanaka H (eds). Oxford Textbook of Public Health, Fourth Edition. Volume 3 The Practice of Public Health. Oxford, Oxford University Press, 2002, pp 1823-1837.

611. Altenburg HP, Agudo A, Berrino F, Boshuizen HC, Bueno-de-Mesquita HB, Janzon L, Le Marchand L, Linseisen J, Lukanova A, Rasmuson T, Vineis P, Riboli E, Miller A. Using multiple imputation methods to estimate relative risks in small EPIC lung cancer subsets. In Elio E and Lambert R (eds). Nutrition and lifestyle: Opportunities for cancer prevention. IARC Scientific Publications No. 156, Lyon, IARC Press, 2002, pp 53-54.
612. Berrino F, Boshuizen HC, Bueno-de-Mesquita HB, Altenburg HP, Agudo A, Le Marchand L, Janzon L, Linseisen J, Lukanova A, Rasmuson T, Vineis P, Riboli E, Miller A. Adjustment for smoking in lung cancer analyses in the EPIC cohort. In Elio E and Lambert R (eds). Nutrition and lifestyle: Opportunities for cancer prevention. IARC Scientific Publications No. 156, Lyon, IARC Press, 2002, pp 59-62.
613. Miller AB. Vegetables and fruits and lung cancer. In Elio E and Lambert R (eds). Nutrition and lifestyle: Opportunities for cancer prevention. IARC Scientific Publications No. 156, Lyon, IARC Press, 2002, pp 85-88.
614. Saadatian-Elahi M, Norat T, Bueno-de-Mesquita HB, Clavel F, Gonzales CA, Hallmans G, Key TJ, Krogh V, Miller AB, Tjonneland A, Trichopoulos A, Riboli E. Plasma concentrations of fatty acids in nine European countries: cross-sectional study within the European Prospective Investigation into Cancer and nutrition (EPIC). In Elio E and Lambert R (eds). Nutrition and lifestyle: Opportunities for cancer prevention. IARC Scientific Publications No. 156, Lyon, IARC Press, 2002, pp 215-218.
615. Miller AB. Breast screening. In Nabholz JM, Tonkin KA, Reese DM, Aapro MS, Buzdar AU (eds). Breast Cancer Management, Second Edition. Philadelphia, Lippincott Williams & Wilkins, 2003, pp 519-527.
616. Miller AB. Is mammography screening for breast cancer really not justifiable? In Senn H-J, Morant R (eds), Tumor Prevention and Genetics. Recent results in cancer research. 163. Berlin, Springer, 2003, pp 115-128.
617. Miller AB. The Natural history of cervical cancer. In Cervical cancer, from etiology to prevention. In: Rohan TE and Shah K, (eds). Dordrecht, Kluwer Academic Publishers, 2004, pp 61-78.
618. Miller AB. HPV testing as a screening test: the case against. In Prendiville EW, Davies P (eds) The Health Professionals HPV Handbook 3 HPV and Cervical Cancer; Public Health Perspectives. London, Taylor and Francis 2004, pp 35-43.
619. Miller AB, Goff DC, Bammann K, Wild P. Cohort Studies. In Ahrens W and Pigeot (eds). Handbook of Epidemiology. Berlin Heidelberg, Springer-Verlag, 2005, pp253-285.
620. Miller AB. Screening. In Ahrens W and Pigeot (eds). Handbook of Epidemiology. Berlin Heidelberg, Springer-Verlag, 2005, pp1267-1304.
621. Miller AB, Buring J, Williams OD. Stopping the Carotene and Retinol Efficacy Trial: the viewpoint of the Safety and Endpoint Monitoring Committee. In: DeMets DL,

- Furberg CD, Friedman LM, Eds. *Data Monitoring in Clinical Trials*. New York, Springer, 2005, pp 220-227.
622. Bartsch H, Miller A, Owen R. Tumorprävention. In: Pfeifer B, Preis J, Unger C, Eds. *Onkologie integrativ*. München, Elsevier Urban & Fischer, 2006, pp 36-46.
 623. Anttila A, Ronco G, Lynge E, Fender M, Arbyn M, Baldauf J-J, Patnick J, McGoogan E, Hakama M, Miller AB. Epidemiological guidelines for quality assurance in cervical cancer screening. Chapter 2 in: *European Guidelines for Quality Assurance in Cervical Cancer Screening*. Second Edition. Eds Arbyn M, Antilla A, Jordan J, Ronco G, Schenk U, Segnan N, Weiner HG, Herbert A, Daniel J, von Karsa L. European Commission – Europe Against Cancer. Lyon, International Agency for Research on Cancer, 2008; pp 11-68.
 624. Miller AB. Screening for Cancer: Are we chasing an elusive dream? In: Baines, CJ, Ed. *The Ralut Senior Scholars Symposium*, April 10, 2008. Toronto. Retired Academics and Librarians of the University of Toronto (RALUT) 2008, pp 53-62.
 625. Miller AB. Epidemiological studies. In: Knasmüller S, DeMarini DM, Johnson I, Gerhäuser C, Eds. *Chemoprevention of Cancer and DNA damage by Dietary Factors*. Weiner, Wiley-VCH Verlag, 2009, pp 199-208.
 626. Miller Anthony. Early diagnosis and screening in Cancer Control. Chapter 4 in Elwood JM, Sutcliffe SB, Eds. *Cancer Control*. New York, Oxford University Press, 2010, pp 63-77.
 627. Miller AB. Chapter 12 Prostate Cancer Screening. In Bellizzi KM, Gosney MA (Eds) *Cancer and Aging Handbook: Research and Practice*. First Edition. Hoboken, New Jersey, John Wiley & Sons, Inc 2012, pp 153-161.
 628. Miller AB. Evidence-Based Cancer Screening. In Miller AB (Ed) *Epidemiologic Studies in Cancer Prevention and Screening*. *Statistics for Biology and Health Volume 79*, New York, Springer Verlag, 2013, pp 199-208.
 629. Miller AB. Breast Cancer Screening. In Miller AB (Ed.) *Epidemiologic Studies in Cancer Prevention and Screening*. *Statistics for Biology and Health Volume 79*, New York, Springer Verlag, 2013 pp 263-276.
 630. Miller AB. Prostate Cancer Screening. In Miller AB (Ed.) *Epidemiologic Studies in Cancer Prevention and Screening*. *Statistics for Biology and Health Volume 79*, New York, Springer Verlag, 2013 pp 277-285.
 631. Miller AB. Finale: What Can We Expect from Cancer Prevention and Screening? In Miller AB (Ed.) *Epidemiologic Studies in Cancer Prevention and Screening*. *Statistics for Biology and Health Volume 79*, New York, Springer Verlag, 2013 pp 405-498.
 632. Davis D, Sears ME, Miller AB, Bray R. Microwave/Radiofrequency Radiation and Human Health: Clinical Management in the Digital Age. In Cohen A and Vom Saal FS, Eds. *Integrative Environmental Medicine*. New York, Oxford University Press 2017 pp 223-251.

Letters

633. Miller AB, Dinner PJ. Old fluoroscopy machines. *CMA Journal* 1974; 110:1135.
634. Miller AB, Howe GR. Artificial sweeteners and human bladder cancer. *Lancet* 1977; ii: 1221-1222.
635. Miller AB, Howe GR. Saccharin - the risks and benefits. 1978; *Nature* 273:8.
636. Miller AB. Mortality from Carcinoma of the Cervix. *Lancet* 1978; ii: 469-470.
637. Miller AB. Mortality from Cancer of the Corpus uteri. *CMA Journal* 1978; 119:1275.
638. Miller AB. Mammography in Mass Screening. *Europ. J. Cancer* 1980; 16: 737-739
639. Miller AB. Canadian national breast cancer screening study. *CMA Journal* 1980; 123: 842.
640. Howe GR, Miller AB, Jain M. Re "Total energy intake": implications for epidemiologic analyses. *Am J Epidemiol* 1986; 124:157-159.
641. Miller AB. More on breast cancer screening. *Cancer Forum* 1988 (March); 1-3.
642. Narod SA, Miller AB. Oral contraceptives and genital tract malignancy. *Lancet* 1989; i:376.
643. Miller AB. Breast screening in women under 50. *Lancet* 1991; 338 (8759):113.
644. Miller AB. Re: "Author of Canadian breast cancer study retracts warning." *J Natl Cancer Inst* 1992; 84:1365-1370.
645. Miller AB, Baines CJ, To T, Wall C. Mammography. *Lancet* 1993; 341:439.
646. Miller AB. NBSS revisited - again. *J Natl Cancer Inst* 1993; 85:1771-1772.
647. Miller AB. Miller reply. *J Natl Cancer Inst* 1993; 85:1775-1776.
648. Miller AB. Canadian National Breast Screening Study: response. *Can Med Ass J* 1993; 149:1374-1375.
649. Miller AB. The breast cancer screening controversy continues - reply. *Ann Intern Med* 1993; 118:748-749.
650. Miller AB. May we agree to disagree, or how do we develop guidelines for breast cancer screening in women? *J Natl Cancer Inst* 1994; 86:1729-1731.
651. Freidenreich CM, Howe GR, Miller AB. Re: "A comparison of prospective and retrospective assessments of diet in the study of breast cancer." *Am J Epidemiol* 1994; 140:579-581.
652. Risch HA, Howe GR, Jain MJ, Burch JD, Holowaty EJ, Miller AB. Lung cancer risk for female smokers. *Science* 1994; 263:12068.

653. Risch HA, Howe GR, Jain MJ, Burch JD, Holowaty EJ, Miller AB. Re: Are female smokers at higher risk for lung cancer than male smokers? A casecontrol analysis by histologic typeThe authors reply. *Am J Epidemiol* 1994; 140:1878.
654. Ponten J, Adami HO, Friberg LG, Gustaffson L, Miller AB, Parkin DM, Sparen P, Trichopoulos D. HPV and cervical cancer. *Int J Cancer* 1995; 63:317.
655. Harvey BJ, Miller AB, Baines CJ, Corey PN. The BSE advantage [Response]. *Can Med Assoc J* 1998; 158: 472.
656. Harvey BJ, Miller AB, Baines CJ, Corey PN. Breast self-examination techniques [Response]. *Can Med Assoc J* 1998; 158: 870.
657. Miller AB, Baines CJ, To T. The Gothenburg Breast Screening Trial. First results on mortality, incidence and mode of detection for women ages 39-49 years at randomization. *Cancer* 1998; 83:186-188.
658. Holowaty P, Miller AB, Rohan T, To T. Re: Natural history of dysplasia of the uterine cervix. *J Natl Cancer Inst* 1999; 91:1420-1421.
659. Miller AB, Baines CJ, To T, Wall C. Screening mammography re-evaluated. *Lancet* 2000; 355:747-748.
660. Miller AB. Effect of screening programme on mortality from breast cancer. Benefit of 30% may be substantial overestimate. *Br Med J* 2000; 321:1527.
661. Miller AB, Baines CJ, Wall C. Canadian National Breast Screening Study-2. Results of a randomized trial in women aged 50-59 years. Response to Narod. *J Natl Cancer Inst* 2001; 93:396-397
662. Miller AB, Baines CJ. Detection of breast cancer. Self examination contributes to reduction in mortality. *BMJ* 2001; 322 (7289):793.
663. Miller AB. Screening for breast cancer with mammography. *Lancet* 2001; 358:2164.
664. Miller AB, Chang-Claude, The risk of breast tumors and lifetime history of oral contraceptive use. *Geburtshilfe und Frauenheilkunde* 2002; 62:1219.
665. Sepulveda C, Miller AB. Cytology screening for cervical cancer. *Int J Cancer* 2004; 111:162.
666. Risch HA, Miller AB. Are women more susceptible to lung cancer? *J Natl Cancer Inst* 2004; 96:1560.
667. Andriole GL, Miller AB, Berg CD. Prostate cancer screening. *New Eng J Med* 2009; 361: 204-5.
668. Mousavi SM, Zheng T, Dastgiri S, Miller AB. Age Distribution of Breast Cancer in the Middle East, Implications for Screening. *The Breast Journal* 2009; 15: 677-9.
669. Harvey BJ, Miller AB. First do no harm? *Canadian Family Physician*, 2010; 56: 412.
670. Johnson KC, Miller AB, Hammond SK, Collishaw NE. Analysis of passive smoking

- and breast cancer of limited value. *Arch Intern Med* 2011; 171:1508-9.
671. Bertuccio P, La Vecchia C, Silverman D, Petersen G, Bracci P, Negri E, Li D, Risch H, Olson S, Gallinger S, Miller A, Bueno-de-Mesquita H, Talamini R, Polesel J, Ghadirian P, Baghurst P, Zatonski W, Fontham E, Bamlet W, Holly E, Lucenteforte E, Hassan M, Yu H, Kurtz R, Cotterchio M, Su J, Maisonneuve P, Duell E, Bosetti C, Boffetta P. Reply to: Are cohort data on smokeless tobacco use and pancreatic cancer confounded by alcohol use? *Ann Oncol*, 2011; 22:1931-1932.
 672. Davis D, Miller AB, Phillips A. Mobile phone use and glioma risk: comparison of epidemiological study results with incidence trends in the United States 17 March 2012. <http://www.bmj.com/content/344/bmj.e1147/rr/573983>
 673. Prorok PC, Miller AB, Kramer BS. Response. *JNCI Journal of the National Cancer Institute Advance Access* published April 5, 2012. DOI: 10.1093/jnci/djs206
 674. Davis DL, Miller AB, Philips A. Association of mobile phone use with adult brain cancer remains plausible. *BMJ* 2012;344:e3083
 675. Miller AB, Harvey BJ. Re: Prostate-specific antigen screening can be beneficial to younger and at-risk men. *CMAJ (letters)* 2013. Published January 31.
 676. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. The authors reply. *Am J Epidemiol* 2014; DOI: 10.1093/aje/kwu228.
 677. Bleyer A, Thomas CR, Baines C, Miller AB. Flawed assumptions used to defend screening mammography. *Cancer* 2015;121(2):320–321.
 678. Narod SA, Giannakeas V, Miller AB. RE: Pan-Canadian Study of Mammography Screening and Mortality From Breast Cancer. *J Natl Cancer Inst* 2015; 107(5): djv094 doi: 10.1093/jnci/djv094.
 679. Miller AB, Wall C, Baines CJ, To T. Advanced cancer in the Canadian Breast Screening Trials. *The Breast Journal* 2015; 21(4): 457-8.
 680. Morgan LL, Miller AB, Davis DL. Has the incidence of brain cancer risen in Australia since the introduction of mobile phones 29 years ago? *Cancer Epidemiology* 2016; 44:112-3.
 681. Miller AB. Comment on "Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study" *Br J Cancer* 2017; 117, e2 | doi: 10.1038/bjc.2017.101
 682. Miller AB. Response to Morrell et al's reply. *Br J Cancer* 2017; 117, e8 |doi:10.1038/bjc2017.322.
 683. Prorok PC, Miller AB. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. *Ann Intern Med* 2018 Apr 17;168(8): 605-606. doi: 10.7326/L17-0735.

